Wiki Books

Here you can access all Wiki Books on the medic debate site. If you want to start a new collaborative scientific Wiki book, just click on "Add Child Page" below. Please check that there are no Wiki books published before on the same subject. If there is, we instead recommend you to improve and update the already published wiki book. When filling in the form, all the items,like appropriate category listings etc do not need to be completely filled in if you are insecure about what to do. The adminitrators will fix it later even if it is not perfect directly.

Albarin, Inectable Aloe Vera or Polymannons




To: "Health Freedom, Codex Issues
From: John Hammell
Date: Tue, 6 Nov 2001 13:43:35 -0500 (EST)

IAHF Webmaster: Breaking News, Create New Category: FDA ALBARIN RAIDS

IAHF LIST: The reason you haven't heard from me lately is because I am on the road in St.Petersburg FL assisting The Medical Center for Preventive and Nutritional Medicine of Tampa/St.Pete which got raided by the FDA Oct.11 placing several patients lives in jeopardy.In this article you will learn of the suppression of a remarkable injectable aloe vera treatment. Please help by taking the action steps requested at the end of my article.Please forward this to more people, and if you can help get Joe DiStephano on the air, please let me know. Urgent legal donations are needed by the clinic.


By John C. Hammell, President, International Advocates for Health Freedom POB 625 Floyd V A 24091 USA 800-333-2553

On October 11,2001 120 terrorists from the Food and Drug Administration, Florida Department of Law Enforcement, and the Hillsborough County Sheriff's Office raided alternative cancer clinics in Tampa and St.Petersburg Florida run under the auspices of The Medical Center for Preventative and Nutritional Medicine. Ironically, the raids came exactly one month after the terrorist attack on the World Trade Center/Pentagon, they were conducted by our own government.

What sets this raid apart from other FDA raids is that 80 % of the cancer patients coming to the clinics for treatment with Albarin, an injectable form of Aloe Vera, were going into remission and not a single complaint came from a patient. The only complaints came from mainstream oncologists obviously solely interested in protecting their economic turf. Many patients lives have been thrown into disarray and several will be dead within a month if they can't get their Albarin back.

If the FDA succeeds in this outrageous effort to suppress patient's access to Albarin, consumers may never again have access to any unapproved treatment they may wish to use, no matter how good it may be. It is essential that everyone take the actions suggested at the end of this article to defend the lives of the patients.

Along with the Tampa and St.Petersburg clinics, the FDA raided the home of Joseph DiStefano, the licensed nutrition counselor who ran them in conjunction with Daniel Mayer, D.O. Their first 100 patients all came from Hospice where they'd been told they only had 2-3 months to live.DiStefano and Mayer only lost 6 out of lOO of them.

Although Albarin is not an FDA approved drug, DiStefano and Mayer had been conducting an INR investigation for its developer, Ivan Danhof, MD, PhD of the N Texas Research Laboratory, Grand Prairie, TX into its uses in the treatment of pain in prostate cancer. Danhof had filed an application for an Investigational New Drug (IND) and was on the verge of providing the FDA with data to support this application, when the raid occurred. They were prepared with solid clinical data from over 30 patients charts to prove that Albarin has a powerful immune enhancing effect while blocking the blood supply to cancer cells, causing rapid diminishing of their size and killing them.

Instead of storming in with this raid which is now jeopardizing lives, the FDA should have simply visited the clinics for the sake of friendly communication to find out what DiStefano, Mayer and Danhof were doing to make sure they were acting in compliance with the law. By conducting this Nazi styled raid, the FDA has grossly violated their mandate to safeguard the public health and they've betrayed our trust. Instead of protecting the public in this case, their actions are directly threatening people's lives.

US Attorney's Office spokesman Steve Cole would not comment on the investigation and U.S. Judge Thomas Mc Coun III sealed the search warrant affidavits used to justify the search warrants for 120 days, as the government seeks to cook up some "justification" for this illegal fishing expedition.

Judging from what was said during the raid, the trumped up charges will most likely include dispensing unapproved drugs, and for Joe DiSteffano, practicing medicine without a license. This charge against DiSteffano is absurd because he has never held himself out to be a doctor, he's been legally working for 38 years as a licensed nutrition counselor always alongside a licensed medical practitioner, in this case, Mayer, an osteopath.

DiSteffano's patients know he is not a doctor, but many of them affectionately call him "Dr Joe" as a term of respect and appreciation. I didn't meet a single unhappy patient here, they all have nothing but praise for DiSteffano and Mayer stating that they don't charge a cent for their initial consultations, and only charge $1100 for Albarin treatment, no matter how many times they have to come back for treatments and they have always been quite willing to work with their patients financially, turning NO ONE away due to any inability to pay. ($1100. is far less than what mainstream oncologists typically charge for a weeks worth of chemotherapy.)

DiStefano and Mayer are without question two of the kindest, most altruistic men I've ever met. Now that they have been raided, they're in desperate need of donations for their legal fund because they aren't making much money at all running these clinics where the primary focus has been to simply help people, not to make money.

Paul Schebell, Margaret Marsh, Karen Kyper, Ruth Hannah, Will Weinand, James Strickland, Robert Banks, and Robert Scofield are among the terminally ill cancer patients who have just been issued death sentences by the Food and Drug Administration Their medical records were seized in the raid, along with Albarin, and your help is urgently needed to defend their lives in the face of this insanity. They could all be dead soon unless they can resume Albarin treatment.


This FDA fishing expedition began a week before the raid when DiStefano exited his office at midnight only to catch FDA Senior Special Agent Rande Mattison and another FDA accomplice trespassing on clinic property, illegally rummaging through his dumpster with rubber gloves on. Trespassing this way was an immense screw up on the part of Mattison who failed to notice DiStefano's car parked in the clinic parking lot and so wrongly believed no one was there.

When DiStefano demanded to know what they thought they were doing trespassing on his property, they had the nerve to tell him they were merely "searching for boxes." "Sure you are, with rubber gloves on at midnight- everyone ALWAYS looks for boxes with rubber gloves on at midnight, you can't legally come on my property without a search warrant, do you have one?" DiStefano proceeded to write down their license plate number while telling them he was going to call the police. "Good" Mattison sneered. They were about to drive away when DiStefano demanded that they put back all the garbage they had removed from the dumpster, but Mattison scowled and tersely informed him that they didn't have to, but his partner said "yes, we do" and he put all the garbage back. Mattison peeled out of the driveway. On the day of the raid in which all Albarin, and patients charts were seized, Mattison pulled DiSteffano aside and told him they were going to "get him" for "practicing medicine without a license."


Shortly before the raid, when DiStefano attempted to mail over 30 patient charts with carefully presented data intended to be used by Ivan Danhof, MD, PhD the Texas researcher who had spent over 30 years developing Albarin to apply for a compassionate use IND, the box was mysteriously RETURNED to him marked "refused by addressee." Danhof never received the package, and he and DiStefano now speculate that the FDA may have been monitoring their mail and that they may have blocked Danhof's receipt of the data as part of their ongoing effort to block public access to this highly successful alternative cancer treatment.

DiSteffano's mail was routinely 3 days late in arriving, and took an extra 3 days to be sent anywhere. His mailman told him that it was being held, but he didn't know why.

Will this terrorist attack soon be another documented case of government genocide as the FDA continues to flaunt their mandate to protect the public health while providing a protection racket defending the profits of such mainstream oncology centers as the Moffitt Cancer Center in Tampa Florida?

A week ago I flew to Tampa from Virginia on the urgent request of the Life Extension Foundation to write this article and to do anything possible to assist in the fight back. Having interviewed several patients, and reviewed their medical records, I am horrified by what the FDA has done here. Every Wednesday since the raid, DiStefano's patients have held rallies in front of the Federal Courthouse in Tampa, and I went with them last Wednesday to take pictures and help carry a sign reading "FDA- Give Us Our Albarin Back" Unless the Courts and Congress rapidly intercede to restore these patients access to Albarin, many patients will be dead quite soon, and many more others who had gone into complete remission will see their cancers return.


Ivan Danhof; MD, PhD, the developer of Albarin, is regarded by many to be the leading authority on the aloe vera plant. Working out of the North Texas Research Laboratory in Grand Prairie, TX, Danhof has impeccable credentials B.S in biochemistry, M.S in Nutrition and Microbiology, PhD in Physiology, and an MD with specialties in Internal Medicine and Gastroenterology. He has written 80 research papers throughout his career. Additionally, he has served as a Fulbright scholar in Afghanistan investigating Botanical medicine.

Danhof states that the Aloe Vera mucilaginous polysaccharide is a long chain sugar molecule composed of individual mannose and glucose sugar molecules connected together. There is a wide range in the size of the mucilaginous polysaccharide molecule, and their size determines their healing properties. Albarin consists of very large particles. up to 9000 molecules which are extracted through a patented freeze drying process turning them into a powder, which was then turned into an intravenously applied liquid by a compounding pharmacist. These large molecules are immune modulating, and have a very powerful healing effect on AIDS, Cancer, and many other immune system disorders. This large molecule also causes the body to produce a natural chemical tumor necrosis factor that functions to shut off the blood supply to tumors.

Illustrating the wide range of healing applications of aloe, Danhof states that the small particles. 60-600 molecules reduce inflammation- which is involved in such diseases as ulcerative colitis, arthritis, and gastric reflux. The small particles also help with the reduction of blood sugar in Type I and II diabetes.

Medium sized particles, up to 1500 molecules, are very effective intracellular antioxidants and free radical scavengers. Whereas vitamins and minerals only have antioxidant properties outside the cells, aloe works within the cells to prevent and treat arteriosclerosis, heart disease, and Parkinson's disease. With the ever increasing pollution of the soil, the increase in free radicals and loss of cellular oxygen will only get worse over time. This makes Aloe Vera mucilaginous polysaccharides more important than ever.

Large sized particles, up to 5000 molecules have a direct antibacterial and anti viral effect. This is important with all the new infectious diseases cropping up and older ones becoming more virulent from long term use of antibiotics.

As stated above, the Albarin serum is derived from the largest particles, up to 9000 molecules in size.


The mucilaginous polysaccharide molecule is very fragile. When the leaf of the aloe plant is cut, enzymes in the plant are released, which breaks down the long chain sugars of the mucilaginous polysaccharide into simple sugars, which then results in a loss of the different healing properties. There are very few products on the market that can claim to contain stabilized mucilaginous polysaccharides. Stabilization requires extraction of the musilaginous polysaccharides in a freeze-dried form but also the process must include a way to deactivate the enzymes released in the plant when it is cut. Furthermore, the high concentration of mineral salts found in Aloe Vera gel must be separated from the final extract because they are very irritating to the gut. An aloe product must be very soothing to the gut to promote healing.

Synergism is a property that many of the large Aloe companies tout who do not have the patented technology to extract stabilized mucilaginous polysaccharides. In other words, many of these companies claim that all 100 of the various ingredients found in Aloe Vera must be present for healing to occur. None of these claims have any basis in scientific research, while there is an abundance of research to prove that the mucilaginous polysaccharide is the sole ingredient responsible for all the healing properties attributed to Aloe.


Research by the immunologist Ian Tizard, PhD and virologist Maurice Kemp, PhD from Texas A&M led to the discovery that Aloe mucilaginous polysaccharide is taken into a special leukocyte, the macrophage, and this cell is stimulated to release messenger molecules called cytokines (interferons, interleukines, prostaglandins, tumor necrosis factor and stem cell growth factors. )

Tumors release a chemical that attracts blood circulation so that malignant cells have a supply of nutrition and can keep multiplying. Tumor necrosis factor shuts off the blood supply to the tumor and therefor it dies. All of the immune modulating effects from Aloe contribute greatly to the prevention and healing of malignant cells.

Danhof's Albarin is being shown to successfully treat about 80% of all cancer patients at The Medical Center for Preventative and Nutritional Medicine, and it is criminal that the FDA has seized the Albarin.

(How likely is the FDA to grant an IND given this raid? Typically, the FDA will grant an IND if one in 50 patients respond favorably to a new treatment. DiStefano has had an 80% success rate with Albarin, and it is apparent that many mainstream oncologists fear it as unwanted economic competition- the complete Albarin treatment has only cost patients $1100., regardless of how many treatments may be needed. Thats less than a typical charge for a week's worth of chemotherapy.)

Joe DiStefano started with the Albarin by successfully treating his own cancer. The first lOO patients he used it on all came from Hospice where they had been told they only had 2-3 months to live, and Joe only lost 6 out of 100 of them.




Paul Schebell, 48, from Connecticut, Advanced Metastatic Prostate/Liver Cancer. Had onset in '98, was diagnosed by PSA levels and bonescan. Despite Lupron and hormone shots, the cancer kept progressing. Learning of the Albarin clinics through a chance phone call with a friend, he started on Albarin in July of 2001. Having been told death was imminent, he now feels much stronger mentally and physically. He can now walk much easier and can concentrate well enough to read. The only side effects from the Albarin are chills. He was stunned by the FDA raid saying "It would be almost ludicrous if not so tragic." He said that his chances will be "greatly diminished" if he can't get Albarin. When the FDA raided, he was receiving treatment and the FDA asked everyone if they wanted to stop. Not one hand went up, they all wanted to keep receiving treatment. Schebell was outraged and told them. "We're all adults here making free will choices."

Along with all the other people interviewed, Schebell stated that there had been no charge for the initial consultation, that the full Albarin treatment only cost $1100. No matter how many treatments were necessary. (He along with all patients stated that their mainstream treatment costs had been into the tens of thousands of dollars, some into the hundreds of thousands.) He (along with all patients) stated that at no time did Joe DiStefano ever hold himself out to be a doctor, they knew him to be a licensed nutrition counselor and they all stated that Daniel Mayer, DO was always present to advise them on their treatments. Schebell could be dead within a month unless he can keep getting his Albarin.


Peggy Marsh, 54 from Tampa Florida was diagnosed with Breast Cancer in '94. Diagnosis was made by biopsy, ultrasound, mammogram. She had a radical mastectomy, radiation, and chemo therapy through the Moffit Cancer Center in Tampa. She had 5 lymph nodes become cancerous by the time they did the open biopsy. After every chemo treatment she lay in bed for 5 days unable to move. They made her sick as a dog, very nauseated. The radiation caused multiple infections forcing her to constantly return to the hospital.

She had a grapefruit sized tumor in her liver a year and a half ago and was only given 6 months to live. She credits the Albarin with helping her to beat these odds. She was treated at the bone marrow clinic at Moffit Cancer Center in Tampa by Dr.Karen Fields, who ultimately issued an ultimatum- that she "had to trust" her medical expertise, and that she could only do either the albarin or chemo, but not both, even though Peggy wanted to keep using both and felt that both were vitally necessary in her case. Marsh, who was trained as a nutritionist and is a Cornell graduate, feels that this is an economic control issue, noting that "All of my Albarin treatments cost me only what one week of chemo costs now." She feels strongly that Moffit might be part of the complaint against Albarin to the FDA, and if that's the case, then Field's violated her trust. "I shared with her about the Albarin study, and if she initiated the complaint to the FDA, she is now jeopardizing not only my life, but the lives of all the patients taking Albarin." Marsh could be dead within a month if she can't keep getting her Albarin.


Will Weinand, 54 from Chicago, started Albarin treatment in March of this year due to cancer in his prostate, spine, and hips. He had his prostate removed, but a year later discovered his cancer had spread to his spine and hips. He did hormone therapy and had severe pain in his lower spine at the T -4 and T -5 vertebrae The pain was so bad from this he had trouble getting out of bed and showering. Mainstream doctors told him he should have 21 days of radiation, and that he wouldn't live longer than a year. They told him the best they could do was pain management. After 6 weeks on the Albarin, the pain began to subside and was gone completely in 3 months. A recent MRI showed that the tumor between T -4 and T -5 vertebrae were gone, as well as the tumor in his left hip, but he still has cancer in his right hip and sacrum according to medical testing. He is very worried that the cancer will start spreading again without the Albarin, and is very disappointed that the government is strong arming their way in, stopping his Albarin treatment when it was clearly working. Will could be dead within a month if he can't resume his Albarin treatment.


Pari Thiern, 58 from Tampa FL had her thyroid removed due to cancer but still has lung and lymph node cancer which metastasized to the bone. She had a huge tumor on the left side of her neck that was going to choke her. After having her thyroid removed at McDill Airforce Base, they wanted to also remove the tumor in her neck and give her chemo and radiation. She refused having watched her first husband die from chemo and radiation, electing to try the Albarin after learning of the clinic at a local health food store via her son. Terrified that she could not afford the Albarin treatment, she was put at ease by Joe and Dr.Mayer who told her not to worry about the $1100. Cost, but to just begin her treatment which she did.

When she first started treatment she could not talk due to the tumor in her neck. She'd made four visits to the emergency room due to chronic infections which no antibiotics helped and was always sick with colds. The only side effects from the Albarin was coldness that went away shortly after each treatment. A catscan indicates that she is now free of cancer, and she is doing 100% better. She is terrified that her cancer will now return and pleads for the return of her Albarin saying "I can't believe this is happening in America."Greatly angered that her medical records were seized in the raid, she is now pleading for the President, her Senators and Congressmen to go to McDi11 Airforce base to look at her records and to see for himself how sick she was.


Robert Becks, 58 year old roofer from Clearwater, FL had a softball sized tumor in his neck which started growing 4 years ago and got enlarged a year and a half ago. It was diagnosed by cat scan, xrays and blood tests. It was too late for surgery, which would have been disfiguring. Holding the view that chemicals and radiation CAUSE cancer, it didn't make much sense to him to have mainstream treatments, which he refused. On December 12, 2000 he began Albarin treatment having learned of it by word of mouth. He was told the cost was $1100. which he could only partially afford to pay. He said Joe was "absolutely wonderful" about not pressing him financially and that he still owed the balance of his payment calling DiStefano and Mayer "The good guys with white hats."

Becks had 70 treatments, 4 per week and the Albarin "stopped the tumor right in its tracks". He said that for awhile he was too sick to resume treatments, and during that time the tumor started growing again, but went away again after treatment was resumed. He was able to stop taking morphine for pain due to the Albarin. Along with all the others interviewed, Becks stated that at no time did DiSteffano ever claim to be a doctor, but that he often called him "Doctor Joe" out of respect and appreciation. Along with all the others he stated that Dr.Mayer had always been present to consult on his treatment. Becks stated with regards to the raid. "This is crazy! I need my Albarin! I personally will do everything possible to get it back! The government has issued me a death sentence! Go look at the statistics, even the head of the Moffit Cancer Center did not take his own treatments when he got cancer, he used alternative treatment!"


Miles Cooper from Shelby NC is a gospel singer who has sung in the Grand Ole Opry in Nashville. He had stage 4 prostate cancer with enlarged lymph nodes and his prostate was pushed against his bladder. His PSA was 187 and he was told he had 6 months to a year to live. He learned of the Albarin treatment by word of mouth while discussing his cancer with friends at church and began treatment in April 2001. He had 86 treatments with Albarin and his PSA went from 187 to 0. 9 in 30 days. An MRI showed normal lymph nodes, and that his Prostate was beginning to shrink. Three weeks ago his PSA was 0.19, and his prostate was still shrinking. He is very concerned that without the Albarin his cancer, which is now in remission, will come back Miles is working very hard to help organize his fellow patients, as are several others. His quiet Christian faith is standing in good stead. He sincerely hopes that the courts and Congress will intercede to help get Albarin back, and that everyone reading this will help as well.


It is essential that everyone call their Senators and Congressmen to request an immediate oversight hearing of the FDA to force them to give the Albarin back to Joseph DiStefano and Dr.Mayer so that these patients can resume treatment. You can reach any member of congress via the Capital Switchboard at 202-225-3121. Especially be sure to call Congressman Dan Burton, Chair of the House Government Reform Committee. He had held other hearings to reign in the FDA and he must hold one very quickly to address this matter.

People living in St.Petersburg and Tampa should specifically call Rep Bill Young at 727-893-3191, and Rep Jim Davis at 813-354-9217 Tell them both that people have a right to freedom of choice in healthcare.

Post this on websites, and forward it to everyone you know- several people's lives are in direct jeopardy, and we must work together to help them get their Albarin back.

Forward this to radio and TV talk show hosts who can air this story If you can get Joe DiStefano onto any large radio or TV shows, contact him via The Medical Center for Preventive and Nutritional Medicine Inc.727-344-3134, 813-968-5998.

Badly needed donations for the legal fund for the Medical Center for Preventive and Nutritional Medicine can be made to:

Joe DiStefano Legal Defense Fund
c/o 6701-C 38th Ave. N.
St.Petersburg, FL 33710



Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma?



Already in the early 1940s, it was discovered that leukemias and sarcomas in rats can be healed and prevented by adding certain amino acids and trace elements to their diets.

Prof Thomas Tallberg from Helsiniki continued to develop these research findings into therapeutic modalities available for treatment of human cancers. He also found that when cancer cells receive these amino acids and minerals, their respiratory organs, or mitochondria, change shape and become dense with electrons. The next thing that happens is that the cancer cells transform into normal cells. This means that he has found a method which can correct the metabolic aberration in certain cancer cells, so that they can stop being cancer cells and continue their natural differentiation into normal cells. In many cases, he has thus managed to heal skin tumors in both animals and humans without even leaving a scar!!
He has published controlled clinical studies showing how, among other things, he completely healed 60% of stage 4 malignant melanomas, 90-100% of melanomas of the eye (uveal mealanomas) and 30% of stage 4 kidney cancers, conditions that are normally almost 100% lethal.
He has so far found the formulae for treating malignant melanomas, breast, prostate, kidney and gastrointestinal cancers with great success. He can also treat psoriasis with this method with an almost 100% success rate.

Besides taking one or two scoops of amino-acid/mineral powder each day, Dr Tallberg also recommends  a small amount (50 g) of mammalian brain each day.  According to Tallberg, this has the dual effect of boosting the immune system and providing a balanced intake of essential lipids. He himself sells cans of piglet brain pate, that can be used as spread on bread, mixed with ice cream or served as a dessert resembling pina colada.
He also uses a special kind of autologous vaccine, made from the patient's own tumor tissue, and recommends avoidance of certain types of food nutrients for different types of cancer that can stimulate cancer growth, ie molybdenum for breast cancer patients and zinc for kidney cancer patients.
We can provide the Tallberg protein/mineral powders and mammalian brain and we have plans to create a labaratory for making the autologous cancer vaccines.
Currently, these vaccines cannot be made anywhere on planet earth except in Tallberg’s own labaratory, and as he is presently 77 years old, he is trying to reduce his workload, and therefore does not accept new patients.


Therapeutic intervention: 

Cancer Psychotherapy according to Dr. Frederick B Levenson


Dr Frederick B Levenson started his work doing psychotherapy with cancer patients 1974, when he started working with psychotherapy with a stage IV breast cancer patient, with the primary goal of aiding their capacity to regulate and discharge irritation.

To his astonishment, he discovered that the patient started to get better from her cancer, as she more and more connected to Dr. Levenson in the psychotherapeutic process, and in the end, she was totally free from cancer. He discovered that she was not the only one that could get healed from cancer by using this method, and during the years he refined his techniques, with even better results as a consequence. In a publication from 2010 where the medical records and the records of dr Levenson during a 35 year period were reviewed, one could clearly demonstrate a positive effect on patient longevity and both observed and reported patient quality of life.

In this paper  75 cases treated during 1974 to 2008 were discussed. Almost all patients were diagnosed with "incurable" cancers treated by oncologists at esteemed medical centres. All subjects  within this sample, with the exception of two who died immediately after the initialisation of treatment experienced an improved quality of life according to case records and reviewed documentation- 33 (44%) are still alive, 80% survived for more than five years and 45%survived for more than 10 years. A noticeable trend of improved patient quality of life and longevity had occurred as Levenson refined and improved his treatment methodology over the decades. The patients often sought treatment after a terminal diagnosis and were informed that allopathic biomedical interventions could not alter their prognosis. There seemed to be an improvement in longevity and several spontaneous remissions were noted in the hospital documentation.

The basic principles of the treatment is that cancer is not seen as a disease, but a process, that can be reversed. Everyone has cancer cells in his/hers body all the time, but normally these cells are taken care of by the immune system, so that no serious problems will develop. Cancer cells are embryonic cells that do not complete there maturation process into fully differentiated, adult cells, and Dr Levenson postulates that the reason for this lack of maturation of certain cells lies in early traumas, and lack of adequate emotional support in early childhood as well as later in life.

The typical psychopatological feature for many cancer patients is the so called anaclitic depression, a state characterised by an inability to form constructive, close relationships with a "melting" fusional quality, based on mutual closeness and trust. Cancer patients often have a tendency to take care of everyone else but themselves, forgetting to prioritise their own needs.

In order to heal these, often very early wounds and personality patterns, it is necessary to let the therapist become like a surrogate mother, that "adopts" the patient in order to give support through two 45 minute talks a week plus daily contact over the telephone for a couple of minutes. It is also always possible to call the therapist 24/7 in emergency situations. If you cannot come to the therapist physically, sessions can be performed over a landline telephone or Skype.

With Dr Mikael Nordfors, medical support is also included in the consultations. Dr Levenson cannot take on any new patients at the moment because he is prioritizing educating new therapists.

The cost is 950 Euro/month.

If you are interested, you can contact Dr Mikael Nordfors on telephone +45 31530931 or by e-mail:


Therapeutic intervention: 



Dichloroacetic acid, often abbreviated DCA, is a chemical compound, an acid, and an analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms, it has the chemical formula CHCl2COOH. The salts and esters of dichloroacetic acid are called dichloroacetates.

Chemistry and occurrence
The chemistry of dichloroacetic acid is typical for halogenated organic acids. It is a member of the chloroacetic acids family. The dichloroacetate ion is produced when dissolved in water. As an acid with a pKa of 1.48,[4]
pure dichloroacetic acid is very corrosive and extremely destructive to
tissues of the mucous membranes and upper respiratory tract.[5]
DCA does not occur in nature. It is a trace product of the chlorination of drinking water and is produced by the metabolism of various chlorine-containing drugs or chemicals.[6] It is typically prepared by the reduction of trichloroacetic acid.
Therapeutic use
Owing to the highly corrosive action of the acid, only the salts of dichloroacetic acid are used therapeutically, including its sodium and potassium salts, sodium dichloroacetate and potassium dichloroacetate.
Lactic acidosis
The dichloroacetate ion stimulates the activity of the enzyme pyruvate dehydrogenase by inhibiting the enzyme pyruvate dehydrogenase kinase.[7] Thus, it decreases lactate production by shifting the metabolism of pyruvate from glycolysis towards oxidation in the mitochondria. This property has led to trials of DCA for the treatment of lactic acidosis in humans.[8][9][10][11]
A randomized controlled trial in children with congenital lactic acidosis found that while DCA was well tolerated, it was ineffective in improving clinical outcomes.[9] A separate trial of DCA in children with MELAS (a syndrome of inadequate mitochondrial function, leading to lactic acidosis) was halted early, as all 15 of the children receiving DCA experienced significant nerve toxicity without any evidence of benefit from the medication.[10]
A randomized controlled trial of DCA in adults with lactic acidosis
found that while DCA lowered blood lactate levels, it had no clinical
benefit and did not improve hemodynamics or survival.[11]
Thus, while early case reports and pre-clinical data suggested that
DCA might be effective for lactic acidosis, subsequent controlled
trials have found no clinical benefit of DCA in this setting. In
addition, clinical trial subjects were incapable of continuing on DCA
as a study medication owing to progressive toxicities.

Potential cancer applications
Cancer cells generally use glycolysis rather than respiration (oxidative phosphorylation) for energy (the Warburg effect), as a result of hypoxia that exists in tumors and damaged mitochondria.[12] Usually dangerously damaged cells kill themselves via apoptosis, a mechanism of self-destruction that involves mitochondria, but this mechanism fails in cancer cells.
A study published in January 2007 by researchers at the University of Alberta,[13] testing DCA on in vitro
cancer cell lines and a rat model, found that DCA restored
mitochondrial function, thus restoring apoptosis, killing cancer cells in vitro, and shrinking the tumors in the rats.[14]
These results received extensive media attention, beginning with an article in New Scientist titled "Cheap, ‘safe’ drug kills most cancers".[15] Subsequently, the American Cancer Society and other medical organizations have received a large volume of public interest and questions regarding DCA.[16] Reports have since pointed out that although the study results are promising, no formal clinical trials
in humans with cancer have yet been conducted in the USA and are not
yet final in Canada, emphasizing the need for caution in interpreting
the preliminary results.[16][17]
Some doctors are treating cancer using DCA "off-label",[18][19] which generates controversy in some circles.[18] The off-label use
of prescription drugs is common practice for cancer patients at the
most prestigious medical institutions in the world, especially those
diagnosed with cancers designated as orphan diseases, for which very few government-approved therapies are available. For example, to treat the grade IV brain cancer called glioblastoma, UCLA Neuro-oncology uses some 50 different drugs, only 4 of which are currently FDA-approved to treat glioblastoma.[20] Oral DCA, which has been safely used to treat lactic acidosis for more than 30 years in humans[14] (but see above), is currently in human clinical trials for glioblastoma.[21]
Drs. Akbar and Humaira Khan have since March 2007 treated cancer
patients using DCA off-label at their private clinic, Medicor Cancer
Centres, in Toronto.[22]
They have treated several types of cancer and said on their web site
that some patients "are showing varied positive responses to DCA
including tumour shrinkage, reduction in tumour markers, symptom
control, and improvement in lab tests".[19]
Although, they have not published their results nor reported it at
medical conferences, they have uploaded details of patient responses
and overall statistics on their web site. [23]
Dr. Terry Polevoy, of Kitchener, Ontario, called on the College of
Physicians and Surgeons of Ontario to take away the Khans' licences for
offering a compound that hasn't been proven to shrink tumours in
humans. "They are not oncologists. They should not be making these
decisions. I think they should be disciplined for using this stuff.
That, to me, is unethical, to use something that has never been proved
to do anything." But the College said that it was not their role to say
which therapies a doctor can use.[24]
Dr. Polevoy himself is not an oncologist, but a medical doctor who runs
an acne clinic in Kitchener, Ontario, as well as a web site devoted to
exposing what he considers self-promotion and self-described "quack
remedies" called[25].
The New Scientist later editorialized, "The drug may yet live
up to its promise as an anti-cancer agent – clinical trials are
expected to start soon. It may even spawn an entirely new class of
anti-cancer drugs. For now, however, it remains experimental, never yet
properly tested in a person with cancer. People who self-administer the
drug are taking a very long shot and, unlikely as it may sound, could
even make their health worse."[26]
DCA has been used historically to treat patients with lactic
acidosis, and therefore could arguably enter phase 2 trials in patients
with cancer.[27]
DCA is non-patentable as a compound, though a patent has been filed for its use in cancer treatment.[28] Research by Dr. Evangelos Michelakis has received no support from the pharmaceutical industry.
Concerns have been raised that without strong intellectual property
protection, the financial incentive for pharmaceutical industry
interest is reduced, and therefore clinical trials of DCA may not be
funded.[15][16][17][29] However, other sources of funding exist; previous studies of DCA have been funded by government organizations such as the National Institutes of Health, the Food and Drug Administration, the Canadian Institutes of Health Research and by private charities (e.g. the Muscular Dystrophy Association).
Recognizing anticipated funding challenges, Dr Michelakis's lab took
the unorthodox step of directly soliciting online donations to fund the
After 6 months, his lab had raised over $800,000, enough to fund a
small Clinical Phase 2 study. Dr. Michelakis and Dr. Archer have
applied for a patent on the use of DCA in the treatment of cancer.[31][32]
On 24 September 2007,
the Department of Medicine of Alberta University reported that after
the trial funding was secured, both the Alberta local ethics committee
and Health Canada approved the first DCA Clinical Trial in Cancer.[33] This initial trial is relatively small (enrollment- up to 50 patients in the following 18 months).
The promise of DCA as a cheap, effective and safe treatment for
cancer generated a great deal of public interest. Many people turned to
self-medication. [34][35]
When faced with the high costs of getting Food and Drug Administration approval, estimated by Tufts University to exceed one billion dollars [36],
the chance of getting DCA approved for the treatment of cancer in the
United States is extremely low. This problem is highlighted in the 2007
New York Times article by Ralph Moss titled "Patents over Patients" [37].
Side effects
Reports in the lay press after the 2007 University of Alberta announcement claim that dichloroacetate "has actually been used safely in humans for decades",[38] but the limited scholarly literature suggests side effects of pain, numbness and gait disturbances in some patients.[38] A clinical trial where DCA was given to patients of MELAS (a form of genetically inherited lactic acidosis) at 25 mg/kg/day was ended prematurely due to excessive peripheral nerve toxicity.[39] Dichloroacetate can also have anxiolytic or sedative effects.[6]
Animal studies suggest that the neuropathy and neurotoxicity during chronic dichloroacetate treatment may be partly due to depletion of thiamine, and thiamine supplementation in rats reduced these effects.[40]
However, more recent studies in humans suggest that peripheral
neuropathy is a common side effect during chronic DCA treatment, even
with coadministration of oral thiamine.[41][42]
An additional study reported that 50 mg/kg/day DCA treatment resulted
in unsteady gait and lethargy in two patients, with symptoms occurring
after one month for one patient and two months for the second. Gait
disturbance and consciousness were recovered with cessation of DCA,
however sensory nerve action potentials did not recover in one month.[43]
Studies of the trichloroethylene (TCE) metabolites dichloroacetic acid (DCA), trichloroacetic acid (TCA), and chloral hydrate suggest that both DCA and TCA are involved in TCE-induced liver tumorigenesis and that many DCA effects are consistent with conditions that increase the risk of liver cancer in humans at dosages much higher than used for cancer therapy.[44]
It has been reported that animals and patients treated with DCA have elevated levels of delta-aminolevulinic acid
(delta-ALA) in the urine. A study published in 2008 suggests that this
product may be the cause of the neurotoxic side-effect of DCA by
blocking peripheral myelin formation. ([1])

Therapeutic Substance(s): 
Therapeutic intervention: 



GcMAF-The cancer revolution from Japan



GcMAF - treatment for cancer, aids and immune diseases

It is our immune system that prevents and cures cancer

A macrophage (purple) eats cancer cellsA macrophage (purple) eats cancer cells

The first research was published in 1993 and since then many papers have appeared indicating GcMAF cured Cancer and eradicated HIV by simply activating the immune system.

Dr. Nobuto Yamamoto in Philadelphia was the first, but hundreds of scientists have now worked on this and related projects.

How does GcMAF work?
In a healthy person GcMAF instructs macrophages in our bloodstream to scour our bodies and kill malignancies. But malignant cells like cancer send out an enzyme called Nagalase that neutralises the GcMAF; so the macrophages never get the message to go into action – in this way cancer suppresses the immune system, and cancer cells grow unchecked.

To reverse this, we make GcMAF outside the body, and it is injected once a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours require additional treatment.) HIV can require as little as 16 weeks.

In its role of immune system regulator, GcMAF reverses other diseases that attack the immune system like Osteoporosis, Aids, Hodgkin’s, Lupus, MS, Fibromyalgia, Parkinson’s, various bacterial and viral infections and various types of Immune dysfunction.

Small pre-clinical trials to build the case are again taking place.

Our GcMAF destroying human cancer cells for 72 hours. At 100ng/ml, panel D, cells show an irregular shape and size. They are significantly smaller as if processes of shrinkage had occurred. Cells appear inhomogeneous and both cytoplasm and nucleus appear irregular as if fragmented. Numerous cellular debris can be observed as well as apoptotic bodies. Clusters are much fewer in number and their borders appear less defined.Our GcMAF destroying human cancer cells for 72 hours. At 100ng/ml, panel D, cells show an irregular shape and size. They are significantly smaller as if processes of shrinkage had occurred. Cells appear inhomogeneous and both cytoplasm and nucleus appear irregular as if fragmented. Numerous cellular debris can be observed as well as apoptotic bodies. Clusters are much fewer in number and their borders appear less defined.

Those diagnosed with any of these illnesses, and who have done their own research on it,  are invited to respond. We ask for a copy of diagnostic information and update reports from a physician during and after treatments, to help build the case that GcMAF is a cure for various illnesses, which will help to make it available to the public. Participants are free to stop at any time.

What have we learned?

Dr Yamamoto carefully selected his trials: he took fit people with in the early stages of cancer and HIV, and reported 100% success, with no recurrence after many years. He did not attempt to cure people with large tumours.

Our trials are quite different: most people are over 50, some over 70, with advanced or terminal cancers, with significant tumour mass.

We appear to have had stunning results in 20 percent of cases, and we think we have learned enough to take that figure up to 50% in this 2011 round of trials. GcMAF needs normal levels of vitamin D to function strongly, and those participants see significant tumour shrinkage in 8 weeks. But even in low responders, GcMAF appears to stop the advance of cancer.

We have probably proved GcMAF can work for people up to age 67, with terminal stage 4 cancer, and can completely destroy large tumour mass.

So far those patients who in 8 weeks are cured of symptoms, or whose tumour mass drops significantly, all take exercise, perhaps a 40 minute walk outside each day.

HIV participants should expect to see viral loads drop to zero, and CD4 counts rise by at least 300 points in 16 weeks, and if that doesn't happen we will refund your money.

But the beauty of using your own immune system to cure cancer is that it remembers how to defeat it for the rest of your life: it doesn't come back. And unlike chemotherapy, the side effects are trivial.

Therapeutic Substance(s): 

Hibiscus as medical herb Hibiscus sabdariffa L.


A double-blind, placebo-controlled clinical trial was conducted in 65 men and women, age 30 –70 y, with systolic BP

Daily consumption of 3 c hibiscus tea, an amount readily incorporated into the diet, lowers BP in pre- and mildly hypertensive adults and may prove an effective component of the dietary changes recommended for people at risk of developing hypertension.

Therapeutic intervention: 



From, the free encyclopedia
Please help to improve and modify this text!

Ibogaine is a naturally-occurring psychoactive compound found in a number of plants in nature, principally in a member of the dogbane family known as iboga (Tabernanthe iboga). Ibogaine-containing preparations are used in medicinal and ritual purposes by African spiritual traditions of the Bwiti who claim to have learned it from the Pygmy. In recent times it has been identified as having anti-addictive properties. Ibogaine is an indole alkaloid which is obtained either by extraction from the iboga plant or by semi-synthesis from the precursor compound voacangine, another plant alkaloid. A full organic synthesis of ibogaine has been achieved, but is too expensive and challenging to produce any commercially significant yield.

In the early 1960s, ibogaine was accidentally discovered to cause sudden and complete interruption of heroin addiction without withdrawal in a matter of hours. Since that time it has been the subject of scientific investigation into its abilities to interrupt addictions to heroin, alcohol, and cocaine. Anecdotal reports also suggest that ibogaine may have potential to drive introspection that helps elucidate the psychological issues and behavior patterns that drive addiction or other problems. However, ibogaine therapy for drug addiction is the subject of some controversy. Due to its hallucinogenic properties as well as risks for patients with certain health problems, it has been placed in the strictest drug prohibition schedules in the United States and a handful of other countries.
While ibogaine's prohibition has slowed scientific research into ibogaine's anti-addictive properties, the use of ibogaine for drug treatment has grown in the form of a large worldwide medical subculture.[1] Ibogaine is now used by treatment clinics in 12 countries on 6 continents to treat addictions to heroin, alcohol, powder cocaine, crack cocaine, and methamphetamine as well as to facilitate psychological introspection and spiritual exploration.



[edit] Psychoactive effects
At doses of around 3-5 mg/kg of body weight, ibogaine has a mild stimulant effect. The high-dose ibogaine experience of 10 mg/kg or greater, often called the "flood", most commonly occurs as two distinct phases: the visionary phase, and introspective phase.
The visual phase is characterized by open-eye visuals, closed-eye visuals, and dreamlike sequences. Objects may be seen as distorted, projecting tracers, or having moving colors or textures. With the eyes closed, extremely detailed and vivid geometric and fractal visions may be seen. Subjective reports often include a movie-like recollection of earlier life experiences as well as dreamlike sequences with symbolism of one's present or anticipated future. Other effects in the visionary phase may include laughing, sensations of euphoria or fear, and temporary short-term memory impairment. The visionary phase usually ends after 1-4 hours, after which the introspective phase begins.
The introspective phase is typically reported to bring elevated mood, a sense of calm and euphoria, and a distinct intellectual and emotional clarity. Subjects often report being able to accomplish deep emotional and intellectual introspection into psychological and emotional concerns. It is also during this period that opioid addicts first notice the absence of withdrawal cravings. The duration of the introspective phase is highly variable, usually lasting hours but sometimes lasting days.

[edit] Side effects and safety
One of the first noticeable effects of large-dose ibogaine ingestion is ataxia, a difficulty in coordinating muscle motion which makes standing and walking virtually impossible without assistance. Xerostomia (dry mouth), nausea, and vomiting may follow. These symptoms are long in duration, ranging from 4 to 24 hours in some cases. Ibogaine is sometimes administered by enema to help the subject avoid vomiting up the dose. Psychiatric medications are strongly contraindicated in ibogaine therapy due to adverse interactions. Some studies also suggest the possibility of adverse interaction with heart conditions. In one study of canine subjects, ibogaine was observed to increase sinus arrhythmia (the normal change in heart rate during respiration).[2] Ventricular ectopy has been observed in a minority of patients during ibogaine therapy.[3] It has been proposed that there is a theoretical risk of QT-interval prolongation following ibogaine administration.[4]

There are 12 documented fatalities that have been loosely associated with ibogaine ingestion.[5] Exact determinations of the cause of death have proven elusive due to the quasi-legal status of ibogaine and the unfamiliarity of medical professionals with this relatively rare substance. No autopsy to date has implicated ibogaine as the sole cause of death. Causes given range from significant pre-existing medical problems to the surreptitious consumption of other drugs in conjunction with ibogaine. Most legal and illegal psychoactive drugs are strongly contraindicated during or immediately after ibogaine treatment, which presents a risk in undersupervised or self-treating subjects.

[edit] Therapeutic uses

[edit] Addiction Interruption

The most studied long-term therapeutic effect is that ibogaine seems to catalyze partial or complete interruption of addiction to opioids. An integral effect is the alleviation of symptoms of opioid withdrawal. Research also suggests that ibogaine may be useful in treating dependence to other substances such as alcohol, methamphetamine, and nicotine, and may affect compulsive behavioral patterns not involving substance abuse or chemical dependence.
Proponents of ibogaine treatment for drug addiction have established formal and informal clinics or self-help groups in Canada, Mexico, the Caribbean, Costa Rica, the Czech Republic, France, Slovenia, the Netherlands, Brazil, South Africa, the United Kingdom and New Zealand where ibogaine is administered as an experimental drug. Although the full nature of Ibogaine is still emerging, it appears that the most effective treatment paradigm involves visionary doses of ibogaine of 10 to 20 mg/kg, producing an interruption of opiate withdrawal and craving. Many users of ibogaine report experiencing visual phenomena during a waking dream state, such as instructive replays of life events that led to their addiction, while others report therapeutic shamanic visions that help them conquer the fears and negative emotions that might drive their addiction. It is proposed that intensive counseling and therapy during the interruption period following treatment is of significant value. Some patients require a second or third treatment session with ibogaine over the course of the next 12 to 18 months as it will provide a greater efficacy in extinguishing the opiate addiction or other drug dependence syndrome. A minority of patients relapse completely into opiate addiction within days or weeks. A comprehensive article (Lotsof 1995) on the subject of ibogaine therapy, detailing the procedure, effects and aftereffects is found in, "Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives".[6]

[edit] Chronic pain management
In 1957, Jurg Schneider, a pharmacologist at CIBA, found that ibogaine potentiates morphine analgesia.[7] Further research was abandoned and no additional data was ever published by Ciba researchers on ibogaine/opioid interactions. Almost 50 years later Patrick Kroupa and Hattie Wells released the first treatment protocol for concomitant administration of ibogaine with opioids in human subjects indicating ibogaine reduced tolerance to opioid drugs.[8] Kroupa, et al., published their research in the Multidisciplinary Association for Psychedelic Studies (MAPS) Journal demonstrating that administration of low "maintenance" doses of ibogaine HCl with opioids decreases tolerance.

[edit] Psychotherapy
Ibogaine has been used as an adjunct to psychotherapy by Claudio Naranjo, documented in his book The Healing Journey.[9]

[edit] Recreational use
Casual use of ibogaine in a social or entertainment context is nearly unknown due to its high cost, constrained availability, long duration of effects, and uncomfortable short-term side effects. In the clandestine markets, ibogaine is typically sought as a drug addiction treatment, for ritual spiritual purposes, or psychological introspection.

[edit] History
It is uncertain exactly how long iboga has been used in African spiritual practice, but its activity was first observed by French and Belgian explorers in the 19th century. The first botanical description of the T. iboga plant was made in 1889. Ibogaine was first isolated from Tabernanthe iboga in 1901 by Dybowski and Landrin[10] and independently by Haller and Heckel in the same year using T. iboga samples from Gabon. In the 1930's, ibogaine was sold in France in 8mg tablets under the name "Lambarene". The total synthesis of ibogaine was accomplished by G. Büchi in 1966.[11] Since then, several further totally synthetic routes have been developed.[12] The use of ibogaine in treating substance use disorders in human subjects first observed by Howard Lotsof in 1962, for which he was later awarded U.S. Patent 4,499,096  in 1985. In 1969, Claudio Naranjo was granted a French patent for the use of ibogaine in psychotherapy.

Ibogaine was placed in US Schedule 1 in 1967 as part of the US government's strong response to the upswing in popularity of psychedelic substances, though iboga itself was scarcely known at the time. Ibogaine's ability to attenuate opioid withdrawal confirmed in the rat was first published by Dzoljic et al. (1988).[13] Ibogaine's use in diminishing morphine self-administration in preclinical studies was shown by Glick et al. (1991)[14] and ibogaine's capacity to reduce cocaine self-administration in the rat was shown by Cappendijk et al. (1993).[15] Animal model support for ibogaine claims to treat alcohol dependence were established by Rezvani (1995).[16]

The name "indra extract" in strict terms refers to 44kg of an iboga extract manufactured by an unnamed European industrial manufacturer in 1981. This stock was later purchased by Carl Waltenburg, who distributed it under the name "Indra extract". Waltenburg used this extract to treat heroin addicts in Christiana, Denmark, a squatter village where heroin addiction was widespread in 1982.[17] Indra extract was offered for sale over the internet until 2006, when the Indra web presence disappeared. It is unclear whether the extracts currently sold as "Indra extract" are actually from Waltenburg's original stock, or whether any of that stock is even viable or in existence. Ibogaine and related indole compounds are susceptible to oxidation when exposed to oxygen[18] as opposed to their salt form which is stable. The exact methods and quality of the original Indra extraction was never documented, so the real composition of the product remains uncertain.

Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug dependent human subjects was published by Alper et al. (1999)[19] and Mash et al. (2000).[20]

[edit] Formulations

Pure crystalline ibogaine hydrochloride is the most standardized formulation dosing and typically must be produced by the semi-synthesis from voacangine in commercial laboratories. In Bwiti religious ceremonies, the rootbark is pulverized and swallowed in large amounts to produce intense psychoactive effects. In Africa, iboga rootbark is sometimes chewed, which releases small amounts of ibogaine to produce a stimulant effect. Ibogaine is also available in a total alkaloid extract of the Tabernanthe iboga plant, which also contains all the other iboga alkaloids and thus has only about 1/5th the potency by weight as standardized ibogaine hydrochloride.[21]
Total alkaloid extracts of T. iboga are often loosely called "Indra extract". However, that name actually refers to a particular stock of total alkaloid extract produced in Europe in 1981. The fate of that original stock (as well as its original quality) is unknown.

[edit] Pharmacology

The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously.[22][23] Because of its fairly low potency at any of its target sites, ibogaine is used in doses anywhere from 5 milligrams per kilogram of body weight for minor effect to 30 mg/kg in the cases of strong polysubstance addiction. It is unknown whether doses greater than 30mg/kg in humans produce effects that are therapeutically beneficial, medically risky, or simply prolonged in duration.

[edit] Mechanism and Pharmacodynamics
Among recent proposals for ibogaine mechanisms of action is activation of the glial cell line-derived neurotrophic factor (GDNF) pathway in the ventral tegmental area (VTA) of the brain. The work has principally been accomplished in preclinical ethanol research where 40 mg/kg of ibogaine caused increases of RNA expression of GDNF in keeping with reduction of ethanol intake in the rat, absent neurotoxicity or cell death.[24]

Ibogaine is a noncompetitive antagonist at ?3?4 nicotinic receptors, binding with moderate affinity.[25] Several other ?3?4 antagonists are known, and some of these such as bupropion (Wellbutrin or Zyban), and mecamylamine have been used for treating nicotine addiction. This ?3?4-antagonism correlates quite well with the observed effect of interrupting addiction. Co-administration of ibogaine with other ?3?4-antagonists such as 18-MC, dextromethorphan or mecamylamine had a stronger anti-addictive effect than when it was administered alone.[26] Since ?3?4 channels and NMDA channels are related to each other and their binding sites within the lumen bind a range of same ligands (e.g. DXM, PCP),[27] some "older" sources suggested that ibogaine's anti-addictive properties may be (partly) due to it being an NMDA receptor antagonist.[28] However, ligands, like 18-MC, selective for ?3?4- vs. NMDA-channels showed no drop-off in activity.

It is suspected that ibogaine's actions on the opioid and glutamatergic systems are also involved in its anti-addictive effects. Persons treated with ibogaine report a cessation of opioid withdrawal signs generally within an hour of administration.
Ibogaine is a weak 5HT2A receptor agonist[29] and although it is unclear how significant this action is for the anti-addictive effects of ibogaine, it is likely to be important for the hallucinogenic effects.[30] Ibogaine is also a sigma2 receptor agonist.[31]

[edit] Metabolites
Ibogaine is metabolized in the human body by cytochrome P450 2D6, and the major metabolite is noribogaine (12-hydroxyibogamine). Noribogaine is most potent as a serotonin reuptake inhibitor and acts as moderate ?- and weak µ-opioid receptor full agonist and has therefore also an aspect of an opiate replacement similar to compounds like methadone. Both ibogaine and noribogaine have a plasma half-life of around 2 hours in the rat [6], although the half-life or noribogaine is slightly longer than the parent compound. It is proposed that ibogaine is deposited in fat and metabolized into noribogaine as it is released.[32] Noribogaine shows higher plasma levels than ibogaine and may therefore be detected for longer periods of time than ibogaine. Noribogaine is also more potent than ibogaine in rat drug discrimination assays when tested for the subjective effects of ibogaine.[33] Noribogaine differs from ibogaine in that it contains a hydroxy instead of a methoxy group at the 12 position.

[edit] Analogs
A synthetic derivative of ibogaine, 18-methoxycoronaridine (18-MC) is a selective ?3?4 antagonist that was developed collaboratively by the neurologist Stanley D. Glick (Albany) and the chemist Martin E. Kuehne (Vermont).[34]

[edit] Research

An ibogaine research project was funded by the US National Institute on Drug Abuse in the early 1990s. The National Institute on Drug Abuse (NIDA) abandoned efforts to continue this project into clinical studies in 1995, citing other reports that suggested a risk of brain damage with extremely high doses and fatal heart arrhythmia in patients having a history of health problems, as well as inadequate funding for ibogaine development within their budget. However, NIDA funding for ibogaine research continues in indirect grants often cited in peer reviewed ibogaine publications.
In addition, after years of work and a number of significant changes to the original protocol, on August 17, 2006, a MAPS-sponsored research team received "unconditional approval" from a Canadian Institutional Review Board (IRB) to proceed with a long-term observational case study that will examine changes in substance use in 20 consecutive people seeking ibogaine-based addiction treatment for opiate dependence at the Iboga Therapy House in Vancouver.

[edit] Legal status
Ibogaine and its salts were regulated by the U.S. Food and Drug Administration in 1967 pursuant to its enhanced authority to regulate stimulants, depressants, and hallucinogens granted by the 1965 Drug Abuse Control Amendments (DACA) to the Federal Food, Drug, and Cosmetic Act. In 1970, with the passage of the Controlled Substances Act, it was classified as a Schedule I controlled substance in the United States, along with other psychedelics such as LSD and mescaline. Since that time, several other countries, including Sweden, Denmark, Belgium, and Switzerland, have also banned the sale and possession of ibogaine.

In early 2006, a non-profit foundation addressing the issue of providing ibogaine for the purpose of addiction interruption within establishment drug treatment care was formed in Sweden.[35]

[edit] See also

[edit] References

  1. ^ K.R. Alper, H.S. Lotsof, C.D. Kaplan (2008). "The Ibogaine Medical Subculture". J. Ethnopharmacology 115: 9-24. Retrieved on 2008-02-22. 
  2. ^ [1]
  3. ^ [2]
  4. ^ [3]
  5. ^ [4]
  6. ^ H.S. Lotsof (1995). Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives (Originally published in MAPS Bulletin (1995) V(3):19-26)
  7. ^ Jurg Schneider (assignee: Ciba Pharmaceuticals), Tabernanthine, Ibogaine Containing Analgesic Compositions. US Patent No. 2,817,623 (1957) (pdf)
  8. ^ Patrick K. Kroupa, Hattie Wells (2005): Ibogaine in the 21st Century. Multidisciplinary Association for Psychedelic Studies. Volume XV, Number 1: 21-25 (pdf)
  9. ^ C. Naranjo. The Healing Journey. Chapter V, Ibogaine: Fantasy and Reality, 197-231, Pantheon Books, Div. Random House,ISBN 0394488261, New York (1973)
  10. ^ J. Dybowski, E. Landrin (1901). "PLANT CHEMISTRY. Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it contains, ibogaine". C. R. Acad. Sci. 133: 748. Retrieved on 2006-06-23. 
  11. ^ G. Büchi, D.L. Coffen, Karoly Kocsis, P.E. Sonnet, and Frederick E. Ziegler (1966). "The Total Synthesis of Iboga Alkaloids" (pdf). J. Am. Chem. Soc. 88 (13): 3099-3109. Retrieved on 2006-06-23. 
  12. ^ C. Frauenfelder (1999) Doctoral Thesis, page 24 (pdf)
  13. ^ E.D. Dzoljic et al. (1988): "Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats" Arch. Int. Pharmacodyn. Ther. 294, 64-70
  14. ^ Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., and Carlson J.N. (1991). "Effects and aftereffects of ibogaine on morphine self-administration in rats". Eur. J. Pharmacol 195 (3): 341-345. Retrieved on 2006-06-24. 
  15. ^ Cappendijk SLT, Dzoljic MR (1993). "Inhibitory effects of ibogaine on cocaine self-administration in rats". European Journal of Pharmacology 241: 261-265. Retrieved on 2006-06-25. 
  16. ^ Rezvani, A., Overstreet D., and Lee, Y. (1995). "Attenuation of alcohol intake by ibogaine in three strains of alcohol preferring rats.". Pharmacology, Biochemistry, and Behaviour 52: 615-620. Retrieved on 2006-06-25. 
  17. ^ A Contemporary History of Ibogaine in the United States and Europe
  18. ^ a)Taylor WI (1965): "The Iboga and Voacanga Alkaloids" (Journal?), Pages 203, 207 and 208. Oxidation products: peroxides; indolenine, iboquine and iboluteine. pdf b) Also compare PMID 16959135
  19. ^ Alper et al. (1999) "Treatment of acute opioid withdrawal with ibogaine." Am J Addict. 1999 Summer;8(3):234-42 (pdf)
  20. ^ D.C. Mash, et al. (2000). Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures (pdf). Neurobiological Mechanisms of Drugs of Abuse Volume 914 of the Annals of the New York Academy of Sciences, September 2000.
  21. ^ Jenks CW (2002)
  22. ^ P. Popik, P. Skolnick (1998). Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. The Alkaloids 52, Chapter 3, 197-231, Academic Press, Editor: G.A. Cordell
  23. ^ K.R. Alper (2001). Ibogaine: A Review. The Alkaloids 56, 1-38, Academic Press (pdf)
  24. ^ He, Dao-Yao et al. (2005): "Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption." Journal of Neuroscience, 25(3), pp. 619–628. Fulltext
  25. ^ Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology. 2002 Mar 1;438(1-2):99-105.
  26. ^ Glick SD, Maisonneuve IM, Kitchen BA. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. European Journal of Pharmacology. 2002 Jul 19;448(2-3):185-91.
  27. ^ Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Journal of Pharmacology and Experimental Therapeutics. 1999 Jan;288(1):88-92.
  28. ^ Popik P, Layer RT, Skolnick P (1994): "The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex." Psychopharmacology (Berl), 114(4), 672-4. Abstract
  29. ^ Glick SD et al. (1999): "(±)-18-Methoxycoronaridine: A Novel Iboga Alkaloid Congener Having Potential Anti-Addictive Efficacy." CNS Drug Reviews, Vol. 5, No. 1, pp. 27-42, see p. 35. Fulltext
  30. ^ Helsley S, Fiorella D, Rabin RA, Winter JC. Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. Pharmacology, Biochemistry and Behaviour. 1998 Feb;59(2):419-25.
  31. ^ Mach RH, Smith CR, Childers SR (1995): "Ibogaine possesses a selective affinity for sigma 2 receptors." Life Sciences, 57(4), PL57-62. Abstract
  32. ^ Lindsay B. Hough, Sandra M. Pearl and Stanley D. Glick. Tissue Distribution of Ibogaine After Intraperitoneal and Subscutaneous Administration. Life Sciences 58(7) (1996): 119–122. Abstract
  33. ^ C Zubaran MD, M Shoaib Ph.D, IP Stolerman Ph.D, J Pablo MS and DC Mash Ph.D. Noribogaine Generalization to the Ibogaine Stimulus: Correlation with Noribogaine Concentration in Rat Brain. Neuropsychopharmacology (1999) 21 119-126.10.1038/sj.npp.1395327. [5]
  34. ^ Christopher J. Pace, Stanley D. Glick, Isabelle M. Maisonneuve, Li-Wen Heb, Patrick A. Jokiel, Martin E. Kuehne, Mark W. Fleck. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European Journal of Pharmacology 492 (2004): 159–167.
  35. ^ Stiftelsen Iboga´s web site

[edit] External links

[edit] Further reading

v • d • e

Drugs from TiHKAL


Therapeutic Substance(s): 
Therapeutic intervention: 




Determination of ibogaine and noribogaine in biological fluids and hair by LC-MS/MS after Tabernanthe iboga abuse Iboga alkaloi

Average: 8 (1 vote)
Therapeutic Substance(s): 
Number of included patients: 

Forensic Sci Int. 2008 Mar 21;176(1):58-66. Epub 2007 Nov 19.
Chèze M, Lenoan A, Deveaux M, Pépin G.

Laboratoire TOXLAB, 7 rue Jacques Cartier, F-75018 Paris, France.

Tabernanthe iboga belongs to the Apocynaceae family. In this study, we report the case of a 37-year-old black male working as a security agent in Paris and found dead naked on the beach in Gabon after consumption of iboga. Autopsy revealed a drowning fatality and a myocardial abnormality (myocardial bridging). Samples of blood, urine, bile, gastric content, liver, lungs, vitreous, spleen and hair were taken. Biological fluids were liquid-liquid extracted with saturated NH4Cl pH 9.5 and methylene chloride/isopropanol (95/5, v/v) in presence of clonazepam-d(4), used as internal standard. After decontamination with dichloromethane, hair was cut into small pieces then sonicated for 2h in saturated NH4Cl pH 9.5 before extraction by methylene chloride/isopropanol (95/5, v/v). After evaporation the residues were reconstituted in methanol/ACN/formate buffer pH 3, from which 10 microL were injected into an ODB Uptisphere C(18) column (150 mm x 2.1mm, 5 microm) and eluted with a gradient of acetonitrile and formate buffer delivered at a flow rate of 200 microL/min. A Quantum Ultra triple-quadrupole mass spectrometer was used for analyses. Ionization was achieved using electrospray in the positive ionization mode (ESI). For each compound, detection was related to three daughter ions (ibogaine: m/z 311.4-->122.1, 174.1 and 188.1; noribogaine: m/z 297.4-->122.1, 159.1 and 160.1; clonazepam-d(4): m/z 319.9-->218.1, 245.1 and 274.1). Ibogaine and noribogaine were detected in all autopsy samples. Hair segmentation was not possible as hair was very short and frizzy. Concentrations of 1.2 and 2.5 ng/mg, respectively were detected. Neither other licit or illicit drugs nor alcohol were found. The presence of ibogaine and noribogaine in all autopsy samples was consistent with the recent absorption of Tabernanthe iboga, which was assumed to be responsible of the drowning fatality. The history of exposure, regarding hair analysis, is discussed. LC-MS/MS appears to be the best method for analyzing complex and poorly volatile alkaloids in autopsy samples and particularly in hair, due to the presence of a nitrogen ring and the relatively low concentrations to be measured.

The ibogaine medical subculture.

Average: 8.5 (2 votes)
Therapeutic Substance(s): 
Number of included patients: 
Therapeutic intervention: 

Alper KR, Lotsof HS, Kaplan CD
J Ethnopharmacol. 2008 Jan 4;115(1):9-24. Epub 2007 Aug 25.

Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA.

AIM OF THE STUDY: Ibogaine is a naturally occurring psychoactive indole alkaloid that is used to treat substance-related disorders in a global medical subculture, and is of interest as an ethnopharmacological prototype for experimental investigation and possible rational pharmaceutical development. The subculture is also significant for risks due to the lack of clinical and pharmaceutical standards. This study describes the ibogaine medical subculture and presents quantitative data regarding treatment and the purpose for which individuals have taken ibogaine. MATERIALS AND METHODS: All identified ibogaine "scenes" (defined as a provider in an associated setting) apart from the Bwiti religion in Africa were studied with intensive interviewing, review of the grey literature including the Internet, and the systematic collection of quantitative data. RESULTS: Analysis of ethnographic data yielded a typology of ibogaine scenes, "medical model", "lay provider/treatment guide", "activist/self-help", and "religious/spiritual". An estimated 3414 individuals had taken ibogaine as of February 2006, a fourfold increase relative to 5 years earlier, with 68% of the total having taken it for the treatment of a substance-related disorder, and 53% specifically for opioid withdrawal. CONCLUSIONS: Opioid withdrawal is the most common reason for which individuals took ibogaine. The focus on opioid withdrawal in the ibogaine subculture distinguishes ibogaine from other agents commonly termed "psychedelics", and is consistent with experimental research and case series evidence indicating a significant pharmacologically mediated effect of ibogaine in opioid withdraw

Ketamine in the treatment of Depression


When treating patients suffering from complex regional pain syndrome (CRPS) with a low-dose (subanesthetic) ketamine infusion, it was observed that some patients made a significant recovery from associated depression. This recovery was not formally documented, as the primary concern was the treatment of the patient's pain. It was not possible to quantify to what degree depression recovery was secondary to the patient's recovery from CRPS. Based on this result, it was thought that a low-dose (subanesthetic) infusion of ketamine was worth a trial in patients who were suffering from treatment-resistant depression without other physical or psychiatric illness.

Correll, et al gave ketamine intravenously to patients commencing at 15–20 mg/h (0.1–0.2 mg/kg/h) and the dose increased until a maximum tolerated dose was achieved. This dose was assumed to be a therapeutic dose and was maintained for 5 days. Patients were able to eat, drink, watch television, or read. They could feel inebriated and/or unsteady when walking. If hallucinations occurred, the dose was to be reduced. The patients' normal medications were continued as it was feared that stopping them might result in severe depressive episodes. Before and following each treatment with ketamine, at patient clinic visits, the Beck Depression Inventory (BDI) and the Hamilton Rating Scale for Depression (HAMD-17) were obtained. Two of the patients were described with impressive[weasel words] improvement in depression being maintained for 12 months in patient A and recurrence at 2.5 months and 9 months in patient B.[24]

The National Institute of Health News reports that a study of 18 patients has found that ketamine significantly improved treatment-resistant major depression within hours of injection.[25] The improvement lasted up to one week after the single dose.[26] The patients in the study were previously treatment resistant, having tried an average of six other treatments that failed. NIMH director Dr. Thomas Insel said in the paper:

"To my knowledge, this is the first report of any medication or other treatment that results in such a pronounced, rapid, prolonged response with a single dose. These were very treatment-resistant patients."

The researchers apparently attribute the effect to ketamine being an NMDA receptor antagonist.[27] Those findings of Zarate et al corroborate earlier findings by Berman et al.[28] However Zarate et al do raise some concerns about their results due to a possible lack of blinding, because of the inebriating effects of low dose ketamine infusion, and it is recommended that future studies include an active placebo.

The findings by Zarate et al. are confirmed by Liebrenz et al, who substantially[weasel words] helped a 55-year-old male subject with a treatment-resistant major depression and a co-occurring alcohol and benzodiazepine dependence by giving an intravenous infusion of 0.5 mg/kg ketamine over a period of 50 minutes and Goforth et al who helped a patient with severe, recurrent major depressive disorder that demonstrated marked improvement within 8 hours of receiving a preoperative dose of ketamine and one treatment of electroconvulsive therapy with bitemporal electrode placement.[29]<[30]

However, a new study in mice by Zarate et al. shows that blocking the NMDA receptor is an intermediate step. According to this study, blocking NMDA increases the activity of another receptor, AMPA, and this boost in AMPA activity is crucial for ketamine’s rapid antidepressant actions. NMDA and AMPA are receptors for the neurotransmitter glutamate. The glutamate system has been implicated in depression recently. This is a departure from previous thinking, which had focused on serotonin and norepinephrine. The glutamate system may represent a new avenue for treatment and research.[31]

Krystal et al. retrospectively compared the seizure duration, ictal EEG, and cognitive side effects of ketamine and methohexital anesthesia with ECT in 36 patients.[32] Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity. Ketamine also increased midictal EEG slow-wave amplitude. Thus, a switch to ketamine may be useful when it is difficult to elicit a robust seizure. Faster post-treatment reorientation with ketamine may suggest a lower level of associated cognitive side effects.

Kudoh et al. investigated whether ketamine is suitable for depressed patients who had undergone orthopedic surgery.[33] They studied 70 patients with major depression and 25 patients as the control (Group C). The depressed patients were divided randomly into two groups; patients in Group A, initial HAMD 12,7 (n = 35) were induced with propofol, fentanyl, and ketamine and patients in Group B, initial HAMD 12,3 (n = 35) were induced with propofol and fentanyl. Depressed mood, suicidal tendencies, somatic anxiety, and hypochondriasis significantly decreased in Group A as compared with Group B. The group receiving ketamine also had significantly lower postoperative pain.

Acute administration of ketamine at the higher dose, but not imipramine, increased BDNF protein levels in the rat hippocampus. The increase of hippocampal BDNF protein levels induced by ketamine might be necessary to produce a rapid onset of antidepressant action.[34]

Therapeutic Substance(s): 
Therapeutic intervention: 

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Average: 9.5 (2 votes)
Therapeutic Substance(s): 
Therapeutic intervention: 
Arch Gen Psychiatry. 2006 Aug;63(8):856-64.Click here to read Links A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA. CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health.Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion.Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.

Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in th

Average: 7 (1 vote)
Therapeutic Substance(s): 
Publication type: 
1: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 8; Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J. Laboratório de Neurociências, Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-000 Criciúma, SC, Brazil. Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor. Clinical findings point to a rapid onset of action for ketamine on the treatment of major depression. Considering that classic antidepressants may take long-lasting time to exhibit their main therapeutic effects, the present study aims to compare the behavioral effects and the BDNF hippocampus levels of acute administration of ketamine and imipramine in rats. To this aim, rats were acutely treated with ketamine (5, 10 and 15 mg/kg) and imipramine (10, 20 and 30 mg/kg) and animal behavioral was assessed in the forced swimming and open-field tests. Afterwards, BDNF protein hippocampal levels were assessed in imipramine- and ketamine-treated rats by ELISA-sandwich assay. We observed that ketamine at the doses of 10 and 15 mg/kg, and imipramine at 20 and 30 mg/kg reduced immobility time compared to saline group, without affecting locomotor activity. Interesting enough, acute administration of ketamine at the higher dose, but not imipramine, increased BDNF protein levels in the rat hippocampus. In conclusion, our findings suggest that the increase of hippocampal BDNF protein levels induced by ketamine might be necessary to produce a rapid onset of antidepressant action.

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of the AMPA receptor.

Average: 9 (1 vote)
Therapeutic Substance(s): 
Publication type: 
Biol Psychiatry. 2007 Jul 20; [Epub ahead of print]Click here to read Links Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of alpha-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health & Human Services, Bethesda, Maryland. BACKGROUND: Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression. Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action. METHODS: The learned helplessness, forced swim, and passive avoidance tests were used to investigate ketamine's behavioral effects in mice. Additional biochemical and behavioral experiments were undertaken to determine whether the antidepressant-like properties of ketamine and other NMDA antagonists involve alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor throughput. RESULTS: Subanesthetic doses of ketamine treatment caused acute and sustained antidepressant-like effects. At these doses, ketamine did not impair fear memory retention. MK-801 (dizocilpine) and Ro25-6981, an NR2B selective antagonist, also exerted antidepressant-like effects; these effects, however, were not sustained as long as those of ketamine. Pre-treatment with NBQX, an AMPA receptor antagonist, attenuated both ketamine-induced antidepressant-like behavior and regulation of hippocampal phosphorylated GluR1 AMPA receptors. CONCLUSIONS: NMDA antagonists might exert rapid antidepressant-like effects by enhancing AMPA relative to NMDA throughput in critical neuronal circuits.

Intravenous ketamine therapy in a patient with a treatment-resistant major depression.

File attachments: 
PDF icon Liebrenz.Ketamine-2007.pdf283.26 KB
Average: 7 (2 votes)
Therapeutic Substance(s): 
Number of included patients: 
Publication type: 
Therapeutic intervention: 

Swiss Med Wkly. 2007 Apr 21;137(15-16):234-6.
Intravenous ketamine therapy in a patient with a treatment-resistant major depression.
Liebrenz M, Borgeat A, Leisinger R, Stohler R.

Click here for full text version

Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland.

BACKGROUND: Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms.

OBJECTIVE: To corroborate antidepressant effectiveness of IV ketamine in a patient with a co-occurring substance use disorder for the first time in a European clinical setting.

DESIGN: Open label trial Methods: A 55-year-old male subject with a treatment-resistant major depression and a co-occurring alcohol and benzodiazepine dependence received an intravenous infusion of 0.5 mg/kg ketamine over a period of 50 minutes. Effects were assessed by means of a clinical interview, the 21-item Hamilton Depression Rating scale (HDRS), and the 21-item Beck Depression Inventory (BDI) at baseline, 1 hour, 1 day, 2 days, and 7 days after intervention.

RESULTS: Following the administration of ketamine the subject experienced a significant improvement of his symptoms peaking on the 2nd day post infusion (HDRS from 36 to 16; -56.6%, BDI from 26 to 9; -65.4%). The subject first reported improvements 25 min. into the infusion and continued to describe positive effects throughout the subsequent 7 days. CONCLUSION: Ketamine not only seems to have strong antidepressant effects but also to act very swiftly. These actions were unaffected by an alcohol or benzodiazpine dependence.

Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.

Average: 8 (1 vote)
Therapeutic Substance(s): 
Therapeutic intervention: 
Publication type: 
Number of included patients: 
Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry. 2007 Jul 10;:1-4 Liebrenz M, Stohler R, Borgeat A. Research Group on Substance Use Disorders, Psychiatric University Hospital, Zurich, Switzerland. Background: The intravenous administration of ketamine, an N-methyl-d-aspartate receptor antagonist, results in a great improvement of depression symptoms, but it is not clear for how long. This single-case trial was conducted to explore the duration of improvement and the effects of a second administration on the clinical outcome. Methods: In an open label trial, a 55-year-old male patient with treatment-resistant major depression and a co-occurring alcohol and benzodiazepine dependence received two intravenous infusions of 0.5 mg/kg ketamine over the course of 6 weeks. Depression severity was assessed by means of a weekly clinical interview, the 21-item Hamilton Depression Rating Scale (HDRS), and the 21-item Beck Depression Inventory (BDI). Results: The first ketamine infusion lead to a pronounced improvement of symptoms, peaking on the second day post infusion (HDRS -56.6%, BDI -65.4%). Positive effects started fading by day 7, reaching baseline by day 35. The second infusion was less efficacious: HDRS and BDI were reduced by 43 and 35%, respectively, and returned to baseline by day 7. Conclusion: In this patient with a co-occurring substance use disorder, repeated administrations of ketamine produced positive results. Since the second application has been less efficacious, doses and schedule of administrations need to be further investigated.

Melatonin and breast cancer


article sited from

(NaturalNews) Melatonin is nature's sleeping pill. It is secreted by the light sensitive pineal gland which regulates our biological clock and synchronizes our hormonal-immune network. Our level of melatonin rises with darkness and falls with light. According to Dr. Uzzi Reiss, in his book Natural Hormone Balance, a healthy pineal gland produces 2.5 milligrams of melatonin every twenty-four hours.

Melatonin plays a central role in the natural aging processes of the body. When pineal production begins to diminish, at around age 40, the decline sets off changes in the operation of the body's cells. The physiology of the cell shifts from repair and rejuvenation to aging and degeneration.

Recent studies are now showing that as our levels of melatonin sink, our chances for breast cancer rise. Many women with breast cancer have lower levels of melatonin than those without the disease. Laboratory experiments indicate that lower levels of melatonin stimulate growth of breast cancer cells. Adding melatonin to these cells inhibits their growth.

Breast cancer and melatonin: studies and results

According to a study at the Department of Physiology, Faculty of Science, University of Extremadura, Badajoz, Spain, published in Molecular and Cellular Biochemistry, Oct. 2005, melatonin increases the survival time of animals with untreated mammary tumors.

The aim of the study was to evaluate the therapeutic effect of melatonin on rats with advanced and untreated mammary tumors. Mammary tumors were chemically induced in rats. Following appearance of the tumors, the effect of melatonin was evaluated based on the survival time, tumor multiplicity, and tumor volume up until the death of the animals. Additionally, the variations in prolactin, noradrenaline and adrenaline concentrations, and percentage of NK cells were evaluated after one month of the melatonin treatment.

Results indicate that daily administration of melatonin increased significantly the survival time of tumor bearing animals compared to the control non-melatonin receiving rats. However, the lengthened survival time did not correlate with changes in either tumor multiplicity or growth rates. Animals with mammary tumors exhibited increased levels of prolactin and catecholamine concentrations compared to the healthy animals. The administration of melatonin stabilized the hormone levels, returning them to the levels of the healthy animals. Rats with mammary tumors also presented lower percentages of NK cells, however these levels were not increased with the administration of melatonin. Researchers concluded that melatonin is beneficial during advanced breast cancer. It increases survival time, perhaps by improving the homeostatic and neuroendocrine equilibrium which is imbalanced during advanced breast cancer.

As published in the International Journal of Cancer, January, 2006, researchers at the Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain, found that melatonin inhibits the growth of induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. They note that melatonin inhibits the growth of breast cancer cells by interacting with estrogen-responsive pathways, effectively behaving as an anti-estrogenic hormone. They had previously described that melatonin reduces aromatase expression and activity in human breast cancer cells, thus modulating local estrogen biosynthesis.

To investigate the in vivo aromatase-inhibitory properties of melatonin in the current study, the indoleamine was administered to rats bearing induced mammary tumors ovariectomized and treated with testosterone. In these castrated animals, the growth of the estrogen-sensitive tumors depended on the local aromatization of testosterone to estrogens. Ovariectomy significantly reduced the size of the tumors while the administration of testosterone to ovariectomized animals stimulated tumor growth, an effect that was suppressed by administration of melatonin or the aromatase inhibitor aminoglutethimide. Uterine weight of the rats, which depended on the local synthesis of estrogens, was increased by testosterone, except in those animals that were also treated with melatonin or aminoglutethimide. The growth-stimulatory effects of testosterone on the uterus and tumors depended exclusively on locally formed estrogens, since no changes in serum estradiol were appreciated in testosterone treated rats.

Tumors from animals treated with melatonin had lower microsomal aromatase activity than tumors of animals from other groups, and incubation with melatonin decreased the aromatase activity of microsomal fractions of tumors. Animals treated with melatonin had the same survival probability as the castrated animals and significantly higher survival probability than those not castrated.

Researchers conclude that melatonin could exert its antitumoral effects on hormone dependent mammary tumors by inhibiting the aromatase activity of the tumoral tissue.

And in the April, 2007 edition of Oncology Report, this same research team at the University of Cantabria, Santander, Spain, reports the effects of MT1 melatonin receptor over-expression on the aromatase-suppressive effect of melatonin in human breast cancer cells. They note that a major mechanism through which melatonin reduces the development of breast cancer is based on its anti-estrogenic actions by interfering at different levels with the estrogen-signaling pathways.

Transfection of the MT1 melatonin receptor in the breast cancer cells significantly decreased aromatase activity, and MT1-transfected cells showed a level of aromatase activity that was 50% of vector-transfected cells. The proliferation of estrogen-sensitive cells in an estradiol-free media but in the presence of testosterone (an indirect measure of aromatase activity) was strongly inhibited by melatonin in those cells over-expressing the MT1 receptor. This inhibitory effect of melatonin on cell growth was higher on MT1 transfected cells than in vector transfected cells. In MT1-transfected cells, aromatase activity was inhibited by melatonin. The same concentrations of melatonin did not significantly influence the aromatase activity of the vector-transfected cells. MT1 melatonin receptor transfection induced a 55% inhibition of aromatase expression in comparison to vector-transfected cells. Additionally, in MT1-transfected cells, melatonin treatment inhibited aromatase expression and induced a higher down-regulation of aromatase expression than in vector-transfected cells.

The researchers concluded that their findings point to the importance of the MT1 melatonin receptor in mediating the oncostatic action of melatonin in human breast cancer cells, and confirm the MT1 melatonin receptor as a major mediator in the melatonin signaling pathway in breast cancer.

Supplementing with melatonin

Since production of melatonin by the pineal gland begins to decline at age 40, it follows that anyone over the age of 40 may be melatonin deficient and may benefit from supplementation as a preventative. Since melatonin is produced while you sleep, it also follows that if you do not get enough sleep, your levels of melatonin may be deficient. Enough sleep is 8 or more hours. Supplementing with melatonin may also be indicated for those who now have or once had breast cancer.

Your melatonin level can be measured with a simple blood test.

According to Dr. Reiss, you should not take melatonin if you have exhausted adrenal glands, symptomized by constant fatigue, low blood pressure, feeling faint when standing up, and low tolerance for physical and emotional stress. Melatonin can reduce the production of cortisol and would be contraindicated for this condition. When adrenal glands are again healthy, supplementation can be started. Women who are trying to conceive should not take melatonin as it could negatively impact the ovulation process.

Melatonin supplements are synthesized to be bio-identical with your own melatonin. They are available at health food stores in capsules, sublingual drops, pills, and as an oral spray.

For anti-aging, Dr. Reiss recommends starting with 0.25 to 0.5 milligrams and increasing the dose gradually until you notice a side effect. The optimal dose is usually 1 to 5 milligrams.

Side effects from excess melatonin are drowsiness upon waking, wild dreams that are not pleasant, waking up nervous, sweating, or with palpitations, and decreased estrogen and progesterone levels.

There is disagreement among authorities as to whether higher doses of melatonin should be recommended for cancer prevention. Dr. Reiss recommends 20 to 40 milligrams daily for prevention. He notes that participants in studies using these very high doses did not develop the side effects seen at lower doses.

Dr. John Lee, in his book What Your Doctor May Not Tell You About Breast Cancer, says that high melatonin levels reduce the ovarian production of estrogens and progesterone, and this is the feedback that is thought to be protective against breast cancer. However, he stresses that all the body's hormones must be in balance, and more is not better when it comes to melatonin. He recommends supplementing with no more than 1 milligram of melatonin sublingually just before bedtime.

If you choose to rely on you own production of melatonin, be aware that production of melatonin rises from bedtime until the middle of the night, and then slowly declines throughout the rest of the night. This production is dependent on you sleeping in a dark room. If you get up during the night and turn on the light or open the refrigerator door, your melatonin production will abruptly stop.

Therapeutic Substance(s): 

Psorinum, the anti cancer miracle from India.

At the ASCO(American Society of Clinical Oncology) congress in Chicago from June 4th to 8th 2010, the world's most prestigious congress of clinical oncology with 30 to 35,000 participants, was published on the poster section a rather sensational result in the treatment of non-small cell lung cancer with an increase of five year survival from an expected <1% to 44%!!
There are also extremely good results in the treatment of gastro.intestinal cancers.
by Aradeep Chtterjee et al from Calcutta, India.
Although, great advances have been made in the treatment of some forms of cancer and new advances in surgery, radiotherapy, and chemotherapy leading to an increase in cure rates have been achieved, such interventions are often too much expensive and beyond the reach of many cancer patients of the developing as well as of the developed countries. In developing countries, majority of the cancer patients have inadequate access to the mainstream cancer treatments due to lack of proper medical infrastructures, skills, and above all limited financial resources.
Some types of cancer (i.e., liver, gall bladder, pancreatic, and stomach) are still associated with poor prognosis to conventional cancer treatments.
Side effects of the chemotherapy and radiation therapy are also intolerable to many cancer patients. In most of the situations, elderly cancer patients cannot be provided with conventional cancer treatments because of old age-related problems . As a result, alternative cancer treatments have become an important feature of oncology regardless of geographic region and they appear to exist in greater abundance through out the world. Many alternative cancer therapeutic modalities are now being practiced in India, and one of them which has gained significant popularity is called Psorinum Therapy .
The investigational anticancer drug used in this alternative cancer therapy is “Psorinum” which is derived from the sphere of homeopathy. The supportive treatments of Psorinum Therapy are adopted both from the spheres of allopathy and homeopathy. Psorinum is an alcoholic extract of the scabies, slough, and pus cells. According to the pre-clinical data, “Psorinum-6x” (“x” stands for decimal potency of homeopathy) activates different immune effector cells (e.g., T cells, and accessory cells like, macrophages, dendritic cells, and natural killer cells) which can trigger a complex antitumor immune response . In a rat model study, daily oral administration of Psorinum 6x at doses up to 0.5 ml/Kg body weight/day for 2 weeks resulted in no adverse side effect  Published retrospective and prospective studies also support the efficacy of Psorinum Therapy in treating patients with various malignancies.
In an observational, open level and single arm study on158 patients with histologically confirmed stomach, gall bladder, liver and pancreatic cancer, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) of cases The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. There were 42 stomach cancers, 40 gall bladder cancers, 44 pancreatic cancers and 32 liver cancers included in the final analysis of the study. 
Some other homeopathic medicines were also used for supportive care:
Table 1
Details of the frequently used homeopathic medicines for the purpose of the supportive cares.
NameOriginDosingPowerUsed to control ailments
(1) Chelidonium majus Herb-Chelidonium majus Up to 0.04 ml/Kg body weight/day orally Mother tincture (1) Abnormal liver functions
 (2) Dysponea
(2) Carduus marianus Herb-Carduus marianus Up to 0.04 ml/Kg body weight/day orally Mother tincture (1) Abnormal liver function
 (2) Cholestasis
(3) Baryta carbonica Barium carbonate Up to 0.02 ml/Kg body weight/day orally 200c (1) Anaemia
 (2) Cancer-related pain
(4) Conium maculatum Herb-Conium maculatum Up to 0.02 ml/Kg body weight/day orally 200c (1)Heart troubles
(2) Abnormal blood pressure
(5) Carbo animalis Animal charcoal Up to 0.02 ml/Kg body weight/day orally 200c (1) Cough
(2) Constipation
(6) Bryonia alba Herb-Bryonia alba Up to 0.02 ml/Kg body weight/day orally 200c (1) Dysponea
(2) Cancer-related pain
(7) Medorrhinum Gonorrhoeal cocci Up to 0.02 ml/Kg body weight/day orally 200c (1) Abnormal blood sugar
(2) Cancer-related pain
(8) Thuja occidentalis Herb-Thuja occidentalis Up to 0.02 ml/Kg body weight/day orally Mother tincture (1) Abdominal distension
(2) Electrolytic imbalance
(9) Cholesterinum Cholesterine Up to 0.02 ml/Kg body weight/day orally 200c (1) Abnormal liver function
(2) Cholestasis
(10) Lycopodium clavatum Herb-Lycopodium clavatum Up to 0.02 ml/Kg body weight/day orally 200c (1) Abdominal distension
(2) Cancer-related pain
 (5.95%) participants were dropped out from the study as they opted for conventional cancer treatments, among them 4 of stomach, 2 of gall bladder, 3 of pancreatic, and 1 of liver cancers.  Among the 158 participants, 84 (53.16%) were male and 74 (46.84%) were female. According to the AJCC TNM staging system, 39 (24.68%) were diagnosed at stage-III, and 112 (70.89%) were diagnosed at stage-IV. The participants' Karnofsky status was between 40–70%, and Eastern Cooperative Oncology Group (ECOG) status was between 2-3. Among the 39 participants (24.68%) who were diagnosed at stage-III, 13 (33.33%) had complete response and 16 (41.03%) had radiological partial response. Among the 112 (70.89%) participants who were diagnosed at stage-IV, 12 (10.71%) had radiological complete response and 38 (33.93%) had radiological partial response
In this study, no adverse side effects were observed from the drug Psorinum. However, very few patients reported to have mild oral irritation and skin itching which were successfully controlled by the supportive cares. Psorinum Therapy was also effective in improving the disease symptoms and the quality of life of the participants. At least 60% participants of stage-III and at least 45% participants of stage-IV reported that the therapy was effective in reducing their cancer-related pain, cough, dysponea, nausea and vomiting, fatigue, constipation and improving appetite, and weakness. These were also confirmed after examining the participants clinically. Improvements were also observed in the lab investigations like Complete Blood Count (CBC), Liver Function Test (LFT), Kidney function test, AFP level, and CA 19.9. These lab investigations were done as a part of their routine clinical check ups. Among the 158 participants, 98 (62.03%) were aged 65 years or more. Better outcomes were observed among the participants below 65 years of age than the participants who were over the age of 65. The outcomes did not vary significantly while considering gender.
Table 2
TNM Staging, partial and complete tumor response in each cancer type.
Primary cancer typesNo. of participantsTNM Staging of the participantsNo. of patients: Complete tumor response occurredNo. of patients: Partial tumor response occurred
Diagnosed at stage-II and stage-IIIDiagnosed at stage-IV
Stomach 42 11 31 6 (14.29%) 16 (38.1%)
G. Bladder 40 13 27 7 (17.5%) 17 (42.5%)
Pancreas 44 9 35 8 (18.18%) 13 (29.55%)
Liver 32 13 19 7 (21.87%) 10 (31.25%)
Table 3
Survival outcomes in each cancer type.
Primary organ affectedNo. of PatientsMaleFemaleSurvived at least 1 yearSurvived at least 2 yearsSurvived at least 3 yearsSurvived at least 4 yearsSurvived at least 5 years
Stomach 42 22 20 34 24 21 20 16 (38.1%)
G. Bladder 40 21 19 32 25 20 18 15 (37.5%)
Pancreas 44 24 20 34 28 27 21 17 (38.64%)
Liver 32 17 15 26 22 19 17 14 (43.75%)
The cumulative 5-year survival was 39.24% for patients who received Psorinum treatment, compared with an estimated 5-year survival of 23% for stomach cancer, 10% for liver cancer, <4% for pancreatic cancer and <15% for gall bladder cancer for patients taking conventional therapies. 28 patients (17.72%) had a complete recovery from their cancer in this study.
Psorinum in the treatment of Non Small Cell Lung Cancer(NSCLC)
In another phase II, open-level, single arm, and single stage  study, also performed by Dr Chatterje et al, 95 participants were included with NSCLC.
According to the AJCC TNM staging system, 58 (61.05%) of them diagnosed at stage IV. According to the RECIST criteria, complete tumor
response occurred in 19 (20%) cases and partial tumor response occurred in 28 (29.47%) cases. 82 (86.32%) of them survived at least 1 yr, 70
(73.68%) survived at least 2 yrs, 58 (61.05%) survived at least 3 yrs, 49 (51.58%) survived at least 4 yrs, and 42 (44.21%) of them survived at
least 5 yrs. These participants did not receive chemotherapy, radiation therapy, or any other investigational cancer treatments. Participants
reported no side effects from the drug psorinum.
Regarding pancreatic cancer:
44 patients participated in the study with Psorinum D6, 0,02 ml per kg body weight in the morning on empty stomach. Survival after first year 34,
after 2 years 28, after 3 years 27, after 4 years 21, and after 5 years 17 of the patients were still alive, equal to a 5-year survival of 39% - Probably the highest ever recorded 5 yearr survival on Pancreatic  Cancer published so far in medicine history!!
These results were examined by a very critical an independent expert commission at the National Cancer Institute in Bethesda, near Washington DC, USA, who has accepted the results, so that Dr. Chatterjee was able to present the results at the ASCO conference. There are plans to make more research on Psorinum on the famous MD Andersson Cancer Institute in Houston,  Texas, USA
The treatment is suitable for many more cancer types, but research has so far been focused on the more difficult cancers.
Dr Mikael Nordfors has been treating a few patients in Europe with Psorinum, with similar results as in India. He also combines psorinum treatment with GcMAF, LDN, Cancer psychotherapy and other immune strengthening treatments
Some of these case stories are published below.
Therapeutic Substance(s): 
Therapeutic intervention: 



Here you can read about others personal experiences related to different aspects of the medical treatment system, health etc.
You can also contribute your own story by clicking on "Add child Page" below.

The story of "Miracle Mineral" and Jim Humble


The Miracle Mineral Supplement of the 21st Century

Parts 1 and 2
Jim V. Humble
3rd Edition

This text is copied from the Preface of the book, in which the first part can be downloaded for free on

What this Book is About
I hope you do not think that this book tells about just another very
interesting supplement that can help some people after taking it for
several months. Not so. This Miracle Mineral supplement works in a
few hours. The #1 killer of mankind in the world today is malaria, a
disease that is usually overcome by this supplement in only four hours in
most cases. This has been proven through clinical trials in Malawi, a
country in eastern Africa. In killing the malaria parasite in the body,
there was not a single failure. More than 75,000 malaria victims have
taken the Miracle Mineral Supplement and are now back to work and
living productive lives.
After taking the Miracle Mineral Supplement AIDS patients are often
disease free in three days and other diseases and conditions simply
disappear. If patients in the nearest hospital were treated with this
Miracle supplement, over 50% of them would be back home within a
For more than 100 years clinics and hospitals have used the active
ingredients in this supplement to sterilize hospital floors, tables,
equipment, and other items. Now this same powerful germ-killer can be
harnessed by the immune system to safely kill pathogens in the human
Amazing as it might seem, when used correctly, the immune system can
use this killer to only attack those germs, bacteria and viruses that are
harmful to the body, and does not affect the friendly bacteria in the body
nor any of the healthy cells. In this book I have, to the best of my ability,
stuck to the facts of exactly what has happened regarding the Miracle
Mineral Supplement.
This book is the story of the discovery and further development of the
most amazing enhancement for the immune system yet discovered. Thus
it is the greatest solution to mankind’s diseases and ills now known; it is
not a drug. I believe if you follow my efforts to develop this data and to
make it available to the public, the story will help make it real to you and
convince you to give it a try. To that purpose I have provided complete
details on how to make the supplement in your kitchen, or to buy most of
the ingredients off the shelf. It is entirely possible that you will save
someone’s life or your own.

Because the Miracle Mineral Supplement functions as a supercharger to
the immune system, it is not meant for treatment of any particular
disease; rather it is meant to improve the immune system to the point of
overcoming many diseases, frequently in less than 24 hours.
My purpose for writing this book is that this information is far too
important to allow any one person, one group or even several groups to
have control. It is information that the world should have. After 5 years
of seeing practically nothing done by a group that could have done a
great deal, I finally realized that the information simply had to be
distributed to as many people as possible or someone would always be
out of the loop of receiving this life saving data. It regularly occurs that
there is a great deal of important medical information withheld from the
public that could save lives. It is my intention to prevent that from
happening with this information.

The story of the cancer medicine Ukrain and Wassil Nowicky


Here is the story of Wassil Nowicky, the inventor of the cancer medicine Ukrain.


Mikael Nordfors, fighting for independent medicine and a subject of "Honor Killings"




My name is Mikael Nordfors. I am a medical doctor and musician and live with my family in Copenhagen.

I am one of the rare doctors that have been have been fighting for democracy, human rigths and freedom of speech in both politics and medicine, and as a consequence of this, I started

the Green Party in Sweden

I started my political career as a co-founding member of the Green Party in 1981, where I was on the parliamentary list and was alternate member of the Trustees. My commitment to the Green Party, however, decreased over time as I noticed that the questions of democracy, which was very central in the beginning began to decline in importance in favor of the corridor talk and manipulation. I also had problems with lying in public issues where my views differed from the party.

the Direct Party

I was therefore pleased when  in 1992 I saw an election poster for 'Phone' Party ", a party founded by the Yellow magazine's founder, Peter Ahlm, who took it upon themselves to organize a referendum in each municipality issues over the phone (internet hardly existed then), and let the party seats in the council guided by the vote results. I then got the idea to combine 
the electronic direct democracy with so called delegated voting, which enabled the participants to give their votes personally selected advisers on issues where they did not have time to vote directly. 

Peter Ahlm did not like the idea, so I instead founded a new national political party called Direct Party.
He Direct Party in their time got some media attention. We were represented in both television and the leading media. I took part in a TV program together with Carl Bildt and Minister Mona Sahlin, titled "Can you trust politicians." 
We got about 150 members, but decided finally not to stand in parliamentary elections due in 1994. lack of resources. Direct Party ran out of steam then when I moved to Norway in 1994 to work as a doctor.

Music Career

During my medical training 1978-1985, I used to worked as a church musician during the summers. In 1985 I got the idea to start playing music on the street, mostly to keep my music-making started while I was working as a doctor. To my surprise I noticed that I thus could both have more fun, more freedom and earn more money than a doctor. This was due to me from 1985 to 1994 mainly living me as a street musician. I also got the manager and record deal and released four albums in record stores with symphonic syntesizermusik.During my time as a musician I also traveled extensively. I was particularlily impressed by the people of Wesrtern Samoa in Polynesia, a society based on social connections and not on private property and career. I am also very interested in meditation and psychotherapy, and did many courses and trainings in this field including Primal Therapy, Encounter, co-counceling, psychodrama, etc. ..

I have since age 14 meditated regularly. I have also given presentations and led workshops on the Danish mystic and philospher Martinus .

After ten years on the streets of Europe, I started to get tired of my travelling life, while also revenue fell due to increasing competition and more and more police restrictions.

My medical career

I started working as a doctor again in 1994 and quickly became very frustrated at the lack of compassion, commitment and competence among my colleagues. I think that the ten years as a street musician and all my therapy experiences had been an excellent way for me to get rid of the brainwashing I have gone through in medical school.

The problem with today's medicine is in a nutshell that 99% of today's doctors would rather sacrifice 100 lives instead of risking their own reputation, and those who are not such as will be ostracized and bullied. We have no evidence-based, but rather eminence-based medicine. 
Since I am a musician and former elite athlete (I was playing volleyball in the top division) and was used to really work hard and do regular training in order to achieve my goals and passions.

When I found a medical problem I could not cope with the official guidelines, I went into the research literature to find new ways, as I often did with success. When I read through all of the latest research on depression treatment, I found to my surprise that there were 30 pieces of double-blind studies showed that herbal medicine St. John's wort was as good as synthetic antidepressants like Prozac to heal depression and that St. John's wort was the most widely prescribed antidepressant in Germany. Not one Swedish and American psychiatry professor had a clue about this!

I happened to know an American psychiatrist and best-selling author whose name was Harold Bloomfield. We decided to publish a book on the subject, ( Hypericum & Depression ) which in ended up in the CNN, Newsweek and the New York Times bestseller list.

I had also started to do research in the social network's impact on schizophrenia, together with Associate Professor Ulf Malm from Sahlgrenska in Gothenburg Paradoxically, in spite of my unusual successes, I later got no job at the Sahlgrenska so I could continue my research there. Most of the Sahlgrenska research was sponsored by the pharmaceutical company Lundbeck, whose best seller was happy pills Cipramil. I was then also very much in the media in connection with the book on St. John's wort and an article on St. John's wort, which came on the front page of the main Swedish medical magazine, ”Lakartidningen”. 
The message from the medical system was were: Go Into the mainstream, read no research, do not care about your patients! 
My analysis of the problem was that the problem in health care was the hierarchical organizational structure, which just released the well-combed yes-men in the hierarchies and more or less banned all independent thought, especially. if you were not a Professor. 
I decided therefore to once again make an attempt to Digital Direct Democracy (DDD).

Vivarto AB

I decided to start a company that would try to sell DDD system to political parties, businesses, municipalities and organizations. At first, I financed a large part of the business by working as a so-called "rental doctor".

We managed to get a working system with delegated voting, which still after 10 years remains unmatched in the world in terms of functionality. We also conducted the first public and secure Internet election in Sweden in Umeå Student Union and the newspaper Aftonbladet (Young Election 2002). I was an invited speaker on the DDD for many political conferences in Sweden and abroad. Several political figures as Mikhail Gorbachev, Madeleine Albright, Benazir Bhutto, Oscar Arias and the Minister Matti Vanhanen was very interested in DDD. 
The nicest compliment in my life I got to the World Political Forum in Turin in 2003 where I was introduced as "The Benjamin Franklin of future World Democracy" by Andrei Grachev, Mikhail Gorbachev's right-hand man and advisor. 
We were very close to our system, sold and implemented by the UN, and Kofi Anan Secretary, who was from England, invited us to headquarters and said that "I can promise you a cup of tea, But I Can not Promise Kofi! 
We sold the system to a host of municipalities and organizations, including the district of Camden in London, Liberal Youth of Sweden and the newly formed DDD lot Vallentuna,
Demoex .

We also worked with the founder of GNU / Linux and the free software movement , Richard Stallman to start a DDD-driven programming company that could compete with Microsoft. One of the ideas was to introduce the equivalent of today's environmental and fair trade banner so that all the companies who donated 10% of their software budget to free software development would be showcasing our symbol. 
The sale was not sufficient to persuade the company to go around, and the dotcom crash in 2001 made it impossible almost fundraising, why Vivarto subsequently went bankrupt 2004th

Victim of "honor killings"

While I was working as rental doctor in order to raise money for Vivarto, showed me a colleague how to cure sciatic and back pain by massaging the sore and tight muscles near the sacrum. These muscles squeeze the nerves that come out from the spinal cord, causing pain and imbalance throughout the body. The syndrome is known outside of Sweden as "the Deep Gluteal Syndrome, or ”thhe Piriformis Syndrome”". I found it hard to believe what I saw, but tried the method in some patients, and added to my surprise noticed that almost every patient became well and asymptomatic immediately!! when I showed this to my colleagues, there almost no interest, despite that they often had seen with their own eyes how patients were able to throw away their crutches and walk out of the treatment room asymptomatic, despite several years of sickness and possibly even disability pension.

Then I met Dr. Stefan Blomberg, who also taught me an injection technique which further increased the effectiveness of treatment. He had in a

his doctoral thesis revealed a 600% reduction of sick leave for those who used his method but nevertheless been neglected by the National Board and the SBU, which are those responsible for the national treatment guidelines in Sweden. However, I myself was having on his reception in one of those high horses' friends wanted to get help with his back. Officially, there were no Stefan Blomberg, but when they needed help themselves, they went there!

I got angry and decided to start a private practice, I called "the guarantee clinic". The idea was that patients would pay a certain sum in advance, which they then would get back if they were not satisfied with the treatment. I got all the most difficult cases in Sweden, which had often been to every specialist in the field without any result, and only had to pay the money back in 30% of cases!

A colleague of mine became angry and asked two patients to report me to the National Board, 1.5 years after I treated them at the district clinic where he was director. 
One of the patients had some bad memory. When reviewing the medical records it was revealed that she actually become symptom free of my treatment and have started to dance folk dance again!

I got two warnings by the National Board. This also went out in the media, so that another patient, who also arrived on the visit and had a good effect of the first reading signed up hoping to raise money for his alcohol abuse.

I appeal Accountability Board's decision in County Court, where I entered as a documentation about 200 scientific references, several double-blind studies, including an MRI study from the U.S. which showed that 70% of all chronic sciatica was due to Piriformissyndrom.The national board was not able a to find one single scientific document that supported their position, and also in spite of this continued to claim that in writing that there was no evidence for the existence of something called ”Piriformis Syndroem”!

I did win the court case with a so big margin, that the appeal from the National board to the higher courts was declined!!

Now you think that this should be a sensation in the media.  Medical doctor can demonstarate in a trial that the National Board of Sweden deliberately rather sacrifice hundreds of thousands Swedes' health rather than losing their face. The whole thing was on the contrary totallt silenced in media. Could it be that the reason for the media silence could be the fact that a large part of the market for painkillers and unnecessary back surgeries would disappear ?

Instead, it was now the time for my hell to start. Someone sent a document dealing with the patient complaints in Sweden and made sure that my employer in Norway launched a campaign of persecution with a lot of complaints from patients that I barely had met, just before the trial result of my victory over the National Board became clear, which led to an article in the major Swedish tabloid ”Aftonbladet” calling me "the anal doctor," in a Tv-show called "Insider" I was (of course totally without any gropund) accused of masturbating in front of my patients, etc. etc. No one wrote about my victory over the National Board. 
Most of these articles is still laying on the Internet, with the result that everyone who googles my name believe I am a perverse sex maniac using ineffective methods of treatment as an excuse to sexually exploit my patients. Things got so bad that many of my friends and relatives no longer wanted to hang out with me because of this.
On top of this, the Norwegian tax authorities declined to let med deduct the costs from trying to start up the above mentioned software programming community together with among else Richard Stallman resulting in a big tax debt for me, in spite of that I even got a witness from Michael Gorbachevs secretary that my e-denmocracy was sincere and serious. As I later found out, I am not the only guy who had theese kind of very unpleasant experiences when speaking up against ”big brother”.

To continue working, I changed name and moved to Denmark, where it was good to work for 1.5 years, until the Danish tabloid Extra Bladet made a front page article with the title"Dr. Anal is now in Denmark" with all sorts of false accussatiopns inside. After that no one dared to employ me in Denmark more. 
This was very tough for me and I was in a period on sick leave due. post-traumatic stress syndrome.

So what happens when you go against the system as a doctor. 
I now work part time at a
holistic cancer clinic in Denmark , where the boss, Dr Finn Skøtt Andersen himself, like most of the Scandinavian alternative doctors have been subjected to similar persecution and completely understand my situation. I also work have aprivate clinic for holistic treatment of cancer and cooperates with the American psychotherapist Frederick B. Levenson to offer my patients a customized type of psychotherapy for cancer patients. I also provide medical advice on both conventional and complementary cancer therapies. I can also help people with chronic back pain, abuse problems, anxiety and depression I have made the Web page, where people publish, discuss and rate articles. My medical dream is to get to an international medical fund to be controlled by a DDD system (not the brainwashed and corrupt medical professors) where you can collect a lot of money for research and support for non-patentable therapies in medicine.

Todoxin, the immune stimulant from Serbia


From, and

Issue 11/1998 of 08/06/1998
Introductory remark

In regard with so called "alternative" medicaments there has been a discussion going on for some time about a preparation called "TODoXIN". There is too little information on the effectiveness of this preparation, but the articles are circulating on the topic of "the medicine: 'TODoXIN'" expressing excitement or rejection. As far as we know, there are no underpinned contributions in which all the knowledge would be critically worked out and summarized. By the following detailed article we wish to fill this gap.


"TODoXIN" is a herbal remedy which has been applied on over 7,000 patients in the cases of different (oncogen) viruses and against HIV-infection effects for 10 years. It was developed by Dr. Todor Jovanovic, a physician born in Vrani Do, Kosovo, in 1935. Dr. Jovanovic studied medicine in Belgrade and finished his specialization in Allergology. After the graduation he carried out research in the UN Research Centre for Nuclear Medicine and in military research centre in Vinca, near Belgrade. The main field of the research was search for histocompatible materials for implantats. Another field of intensive work was the research and monitoring of immunostimulating effects of plant extracts.

In 1987, Dr. Jovanovic applied for a patent on TODoXIN recipe. After that, he made an effort to get the support of experts and institutions in the country and abroad for his projects. There were, among others, the president of Serbian Academy of Science and Art, Dusan Kanazir, Luk Montagnier, the man who discovered HIV, as well as the leader of the special program of WHO for AIDS, Jonathan Man.

Because of the sparse data, no one showed interest for that project, except for the leader of a research group from Austria. With the Austrian partners in the research, Dr. Jovanovic signed a long-term contract on cooperation in 1988. The goal of the cooperation was to test the remedy on the international scale, galenic development and later, submission of the appropriate study results, obtaining the international approval and production.

After it has been proved toxicologically safe in 1988, the Austrian team, in collaboration with the Karolinska Institute for Immunology in Stockholm, in 1988-89, succeeded in showing the immunostimulating properties of TODoXIN in vitro, as well as the development of pharmacodynamic model of effect mechanisms induced on the immuoendocrinal level. That model could have been tested ex vitro and and confirmed in vivo. It was followed by intensive medical observation of its use, in collaboration with some clinical workers and physicians, in a wide spectrum of potential indications for immunostimulating properties of TODoXIN. On the basis of the data obtained by early 1991, the scientists of National Institutes of Health (NIH), in Washington, expressed their readiness to examine TODoXIN in vitro within the "Developmental Therapeutics Program". The studies of HIV culturing proved that cell bearable concentrations of active agents of TODoXIN can inhibit HIV up to 100%.

At the end of 1991 TODoXIN was given the license for production in Yugoslavia under the register number 4684 dd 31/10/88, as a "dietetic product based on honey and medicinal herbs ". The records on HIV- inhibiting capacity of TODoXIN, obtained at NIH, as well as the results of HIV-positive patients treated with TODoXIN since 1988, were not presented until the 10th International Conference on AIDS in Yokohama (1994), because NIH which was late in giving the permission for releasing the data.

On the basis of these data the Austrian research group succeeded in winning over the European virologists and AIDS researchers, prof. Richard Teddar and Dr. Clive Loveday from UCL Medical School of London, to the scientific collaboration. The data jointly won over the years that followed were appraised and designated as “very promising" by members of the British Medical Research Council – MRC and HIV Clinical Trial Centre – prof. A. Brackenridge, prof. D. Jeefries, prof. I. Weller and Dr J. Darbyshire.

On the 11. International AIDS Conference in Vancouver (1996), an official symposium on TODoXIN was held, where the most recent data were presented.

After that, the Department for Retro virology of Royal Free Medical School in London came up with offer to carry out further studies in England under official supervision of pharmaceutical authorities, MRC and one ethical committee. The results of these studies were supposed to support the official request for registration of TODoXIN in the European Union. The study started, after longer preparations, in September 1997, after it had been established that TODoXIN is to be produced in the future by Dr. Jovanovic together with an Austrian partner in the research, within one Austrian firm.

In the course of the study, Dr. Jovanovic decided to accept the offers of English researchers and their American partners to have TODoXIN produced in the USA in the future and to carry out further study over there. In order to present data which were up-to-date in 1998. to American partners, the London study, started in 1997, was interrupted in March 1998, and a new study was started, using the first laboratory samples of American TODoXIN. A separate American study is still about to start this year in California. Therefore, for the precaution sake, no new TODoXIN data were presented in the 12th International AIDS Conference in Geneva.


TODoXIN is made exclusively of plants and does not contain any synthetic components and preservatives.

Plants or parts of plants which are used for preparation are regularly tested for toxins which naturally occur, and for the presence of toxically substances used in agriculture (DDT, Lindan, Dieldrin, Endrin, Hexachlorbenzol, heavy metals, nitrites, nitrates, fungi, aerobic and anaerobic bacteria etc.)

In a joint poster session (abstract PA0340) presented by "TODoXIN Study Group" at 10th International AIDS Conference in Yokohama (1994) to the Department of Immunology of the Karolinska Institute (Sweden) and National Institutes of Health of the USA the composition of TODoXIN was presented in the following way:

"TODoXIN is a novel antiviral and immunostimulating preparation based upon an ion carrier molecule with specific binding affinities and a carrier specific substrate formulation. TODoXIN's formulation is unique in three aspects:

1. It comprises a very broad spectrum of physiologically active, cis-oriented and water soluble carbohydrates, carboxylic acids, vitamins, fat soluble vitamins, coenzymes and enzymes such as Amylases, Phosphates and Catalyses.

2. It contains both agonic and antagonic agents such as Ca and Fe, in physiologically relevant concentrations.

3. It contains a spectrum of minerals in permanent solution."

Micro-nutrients present in TODoXIN are exclusively of plant origin. They are obtained directly from fruits (mainly citrus fruits). Formulation also contains about 20 vol.-% honey.

Herbal active substance is kept in secret by Dr. Jovanovic. At present, there is a patent procedure running on the territory of the Former Yugoslavia. The exact composition, as well as pharmacokinetic data are not available for publication (not even in the editorial office). However, every therapeutic physician who would like to apply TODoXIN can have access to this data.

The up to date experience confirm the following indication:

myelo-proliferative syndrome


acute lymphoblast leukemia

acute myeloid leukemia

malignant lymphoma


testicular tumor, prostate, breast, rectum, cradle, lungs, skin and all gynecologist cancers.


There is hope even in case of very progressive diseases, like in lang metastasis, liver, bones. In many cases when patients were inoperable, because of diffusible infiltration of primary tumor into adjoining tissue and many metastasis even in case of bone decalcification, after TODOXIN therapy, the primary tumor is more clearly differentiated, looses in mass and becomes operable. Metastasis has disappeared, bones have been recalcificated and patients experienced complete remission. This phenomenon is 100 times more frequent than so called spontaneous remission in oncology practice.

However, it is most useful to start TODOXIN therapy as soon as the diagnosis has been established, for the effects are much better if it starts sooner. In progressive stadiums of cancer, a week can sometimes has the same significance as a whole year in different phases of cancer.


TODoXIN is in official use since 1963. Over 1300 HIV1 and 2 infected patients have been treated and the results are:

At patients whose virus serum was observed in short intervals, periodical appearance of HIV1 free virus (RNA virus serum) was noticed in the beginning of therapy during first 14 days of the high dose therapy cycles (taking every 2 hours).


There comes the increasing of 20 times above the average values and after that the gentle decreasing of virus serum which is on the detection limit (up to 4 log) in period between second and sixth week. Further on the value of virus serum constantly decreases (at detection limit, less than 20c/ml) after two to four cycles of the high dose therapy, that is 12-14 weeks.

After 6-18 months, the number of CD 4 cells increases for 50-150% of basic values and it happens with most patients. The time necessary for reaching and exceed the referent values is proportional to time extend of HIV infection before the therapy.

The significant changes during the therapy initiate the introduction of special forward therapy with corresponding dozes. This therapy deduces the clinical symptoms of viremia to minimum (to less than 2%).

Therapeutic Substance(s): 
Therapeutic intervention: